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Fam83d and Dupd1 have been identified as novel genes in skeletal muscle that are upregulated 
in response to neurogenic atrophy in a mouse model. qPCR analysis reveaed both genes are 
expressed in skeletal muscle with Fam83d expression being highest during myoblast 
proliferation, while Dupd1 expression is highest during myotube differentiation. Overexpression 
of either protein results in inhibition of proper muscle cell differentiation as evidenced by 
repression of both myosin heavy chain and myogenin expression. Characterization of 
transcriptional activity revealed both genes are modulated by myogenic regulatory factors and 
additionally, Dupd1 expression is enhanced by dexamethasone treatment. Assessment of 
subcellular localization revealed that Fam83d localizes in a punctate manner in the cytoplasm, 
while the expression of Dupd1 showed ubiquitous distribution throughout the cell. To assess 
function, Fam83d or Dupd1 were ectopically overexpressed in cultured muscle cells. 
Overexpression of Fam83d resulted in significant repression of phosphorylated ERK and AKT. 
Interestingly, inhibition of the 26S proteasome and the MAP kinase signaling pathway both 
resulted in stabilization of Fam83d during muscle cell differentiation. Finally, Fam83d has a 
putative phospholipase D-like domain that appears to be necessary for destabilizing casein kinase 
Iα and inhibiting ERK phosphorylation in cultured myoblasts. Overexpression of Dupd1 resulted 
in significant repression of phosphorylated ERK and AMPK. Additionally, Dupd1 
overexpression resulted in dramatic increases in GR protein as well as phosphorylated GR, while 
attenuating activity of a GRE reporter gene. The discovery that Fam83d and Dupd1 are 
expressed in skeletal muscle combined with the observation that they are induced in response to 
neurogenic atrophy helps further our understanding of the molecular and cellular events of 
skeletal muscle wasting 
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Chapter 1: Background on skeletal muscle atrophy, MuRF1 and cell signaling 
Skeletal Muscle Atrophy 
Muscle atrophy is identified as the reduction in muscle mass and strength. Muscle mass is 
maintained by a balance between protein synthesis and protein degradation. When protein 
degradation outpaces synthesis, atrophy occurs (1). Atrophy can result from a variety of 
conditions including aging, spinal cord injury, immobilization, corticosteroid exposure, and 
denervation (2). Many molecular pathways contribute to muscle degradation, but the full scope 
of these pathway interactions is still unclear. Additional research into muscle degradation 
mechanisms, such as the ubiquitin proteasome system, will help further elucidate these pathways 
and may identify possible targets for future therapeutic intervention.  
 
The Ubiquitin Proteasome System 
The ubiquitin proteasome system (UPS) is one pathway that participates in muscle degradation. 
This pathway consists of three proteins, the E1 ubiquitin activating enzyme, the E2 ubiquitin 
conjugating enzyme and the E3 ubiquitin ligase. A ubiquitin molecule first binds to a cysteine 
residue on the E1 enzyme. The ubiquitin is then transferred to a cysteine residue on the E2 
enzyme. The E2 enzyme transfers the ubiquitin to the target substrate to tag it for degradation. 
This transfer is regulated by the E3 ubiquitin ligase which has a binding site for both the E2 
enzyme and a binding site that is substrate specific (3).  The E3 enzyme is crucial as it provides 
selectivity and specificity to the UPS. The conjugation and ubiquitin transfer continues until the 
substrate accumulates a chain of four or more molecules of ubiquitin which initiates degradation 




















Figure 1. Schematic of the ubiquitin proteasome system. The E1 ubiquitin activating enzyme, E2 
ubiquitin conjugating enzyme and E3 ubiquitin ligase form a pathway to ubiquinate substrates 
for degradation by the 26s proteasome (4).   
 
MuRF1 and MAFbx 
Since E3 ubiquitin ligases provide specificity for the ubiquitin proteasome system, identifying 
muscle specific E3 ubiquitin ligases is a critical component of understanding muscle atrophy 
pathways.  In 2001, a study by Bodine et al identified muscle RING finger 1 (MuRF1) and 
muscle atrophy F-box (MAFbx) as universal markers of muscle atrophy (2). In the study, rats 
were subjected to denervation, hind limb suspension, and immobilization. Muscle tissue was 
then isolated and analyzed for genes showing differential expression between atrophy and 
control conditions in wild-type animals (2). Many genes showed differential regulation in one or 
two of the conditions but only MuRF1 and MAFbx were upregulated in all three conditions (Fig. 
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2). Knockout mice were produced to further examine the role of these two genes and in both 
cases the knockout mice were atrophy resistant compared to control animals (2). MuRF1 
knockouts exhibited 36% muscle sparing and MAFbx knockouts exhibited 56% muscle sparing 
as compared to control (2). While MAFbx knockouts showed a greater percentage of muscle 
sparing, the MuRF1 knockouts showed greater muscle integrity making MuRF1 the preferred 
subject for further study (2). The structure of MuRF1 suggests its role as an E3 ubiquitin ligase 
but to date there has been a lack of clearly identified protein targets (1), which leads to further 








Figure 2. Northern blot displaying mRNA expression of MuRF1 and MAFbx in muscle tissue of 
rats subjected to atrophy induction by immobilization, denervation, and hind limb suspension. 
Expression is observed at day 1 and reaches a peak at day 3 post denervation (2).  
 
MuRF1 as a Transcriptional Regulator 
In 2013, Furlow et al. investigated MuRF1’s role in muscle atrophy more closely using genome-
wide microarray analysis (5). Knockout mice were produced by inserting a β-galactosidase lacZ 
cassette into the MuRF1 gene (2). This insert disrupted the function of the MuRF1 gene and 
produced β-galactosidase when the MuRF1 promoter is active. This construct allowed researches 
to assess endogenous MuRF1 promoter activity without the effect of the functional MuRF1 gene. 
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They compared MuRF1 knockout and control mice under neurogenic atrophy conditions and 
control conditions by harvesting gastrocnemius muscle at 3 and 14 days post-denervation (5). A 
microarray analysis was then performed on harvested muscles to identify genes with differential 
expression at early (3 days) and late (14 days) stages of denervation. In the wild-type (WT) mice, 
MuRF1 expression was elevated at day 3 post-denervation but returned to baseline by day 14. In 
the knockout KO) animals, β-galactosidase expression was also elevated at day 3 but remained 










Figure 3. Transcriptional activity of the MuRF1 gene locus in WT and MuRF1 KO mice 
following sciatic nerve transection. (A) Denervated WT mice showed an increase in MuRF1 
gene expression at day 3 (3D), but returned to baseline at day 14 (14D) post-denervation. (B) 
Denervated KO mice showed at increase in β-galactosidase expression, which is under the 
control of the MuRF1 promoter, at day 3 and expression remained elevated at day 14 post-
denervation (5). 
 
In addition, MAFbx expression varied between the wild-type and MuRF1 knockout mice. 
Denervated wild-type mice showed increased MAFbx expression at day 3 and expression 
returned to baseline by day 14 (Fig. 4). However, in the MuRF1 knockout mice, MAFbx 
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expression was elevated at day 3 and remained elevated at day 14 (Fig. 4). This suggests that 








Figure 4. Transcriptional activity of MAFbx in wild-type and MuRF1 KO mice following sciatic 
nerve transection. (A) Denervated WT mice showed an increase in MAFbx gene expression at 
day 3 (3D), but expression returned to baseline at day 14 (14D) post-denervation. (B) Denervated 
MuRF1 KO mice showed an increase in MAFbx gene expression at day 3 and it remained 
elevated at day 14 post-denervation (5). 
 
Differences in expression were shown for a wide variety of genes when comparing the wild-type 
and MuRF1 knockout mice subjected to atrophy conditions. One of these genes, Family with 
Sequence Similarity 83 D (Fam83d) is the subject of chapter 2, while Dual specificity 
phosphatase and pro isomerase domain containing 1 (Dupd1), is the focus of chapter 3 of this 
thesis.  
 
Myogenic Regulatory Factors (MRFs) 
Myogenic Regulatory Factors (MRF) are transcription factors important to the development of 
muscle tissue and are dramatically upregulated in response to neurogenic atrophy. MRFs 
function by interacting with co-activators and co-repressors within the promoter region of 




motif, which promotes binding to a canonical E-box consensus sequence of 5’-CANNTG-3’ 
(where N can be any nucleotide). These E-box sequences are found in the promoter regions of 
most muscle-specific genes, which includes MuRF1 and MAFbx. MRFs can bind directly to 
these E-boxes and modulate the transcriptional activity of genes that possess these enhancers 
(6,7). 
 
MyoD and myogenin are two such MRFs that have previously been shown to be upregulated 
during neurogenic skeletal muscle atrophy (7). MyoD acts as a marker of myogenic commitment 
to skeletal muscle and is important in maintaining the differentiated state of the cells. It is also 
required for the expression of myogenin, which plays a significant role in muscle cell 
differentiation and viability (7). Myogenin is also required for full induction of MuRF1 and 
MAFbx under neurogenic atrophy conditions (8). In fact, previous studies have shown that 
deletion of myogenin leads to a reduction of MuRF1 and MAFbx and subsequent resistance to 
muscle wasting in mice following denervation (8). 
 
Signal Transduction Pathways Involved in Muscle Growth and Development 
Atrophy is an active process, requiring transcriptional activation and differential regulation of a 
wide variety of genes (9). This can occur through regulation by one or more signaling pathways 
that regulate myogenesis, protein synthesis, and protein degradation (9). MAP kinase signaling is 
an important pathway involved in cell growth, proliferation, and differentiation in a wide variety 
of tissue types (10). The pathway consists of four main branches including, the ERK1/2, p38, 
JNK and ERK5 arms (10). Within each of these branches, growth factor binding to receptor 
tyrosine kinases triggers a signaling cascade that leads to phosphorylation and activation of  
MAP kinase kinase kinases (MAP3Ks), which in turn phosphorylate MAP2Ks to activate them, 
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which then in turn activates MAPKs by phosphorylation as well (10). Each branch triggers a 
unique terminal kinase to translocate to the nucleus to act as a transcription factor to modulate 
the activity of a subset of genes (11). ERK signaling plays a critical role in muscle cell 
proliferation and repression of premature differentiation through prevention of early cell cycle 
exit (11). While ERK signaling is reduced as muscle cells differentiate, ERK1/2 activity has been 
shown to increase again during terminal differentiation and has been found to be critical for 
proper myocyte fusion and survival (12). ERK1/2 signaling likely has a role to play in skeletal 
muscle atrophy as evidenced by improved myogenesis and reduced muscle wasting in cachexic 
mice following treatment with PD98059, an ERK-specific inhibitor (13).  
 
Figure 5. Illustration of MAPK cascades for ERK1/2, JNK, p38, and ERK5. (14). 
 
Previous research also suggests that the AKT signaling pathway is important in muscle atrophy 
and hypertrophy depending on the state of the tissue (11). Activated by insulin-like growth factor 
(IGF), AKT functions to activate expression of pro-survival proteins, such as mTOR, and 
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suppresses expression of apoptotic proteins, such as those in the FoxO family (15).  AKT is 
capable of phosphorylating mTOR which increases activity of downstream targets involved in 
protein synthesis (16). Dephosphorylation of FoxO proteins leads to FoxO translocation to the 
nucleus where it binds to FoxO binding elements (FBE) in the promoter region of various genes 
related to skeletal muscle atrophy (17). AKT phosphorylation of FoxO proteins leads to 
cytoplasmic sequestration and blockage of the activation of atrophy-inducing genes, such as 
MuRF1 (17).  
 
Figure 6. The insulin-like growth factor 1 (IGF1)-Akt pathway controls muscle growth via 
mammalian target of rapamycin (mTOR) and FoxO proteins. (16) 
 
Glucocorticoid (GC) signaling is known to play a role in skeletal muscle atrophy (18,19). 
Increases in GCs lead to decreases in protein synthesis and increases in protein degradation (19). 
The inactive glucocorticoid receptor is found in the cytoplasm bound to a chaperone complex 
containing several proteins including heat shock protein 90 (HSP90) (20). As a ligand-dependent 
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transcription factor, binding of GCs result in the cytoplasmic glucocorticoid receptor (GR) to 
translocate to the nucleus where it may bind to glucocorticoid response elements (GRE) (19). GR 
possesses multiple phosphorylation sites and a dynamic interplay between phosphorylation and 
dephosphorylation events determines its precise role following nuclear translocation (20). In 
addition to transcriptional enhancement though GR homodimer binding to GRE consensus 
elements, ligand-bound GR may translocate to the nucleus and bind to other transcription factors, 
such as AP-1 and KF-κB, and interfere with their ability to function as transcription factors (20). 
GR activation of catabolic pathways including the ubiquitin proteasome system and autophagy 
pathways are thought to play a major role in the molecular mechanisms responsible for skeletal 
muscle atrophy resulting from increased glucocorticoid exposure (18). In fact, both MuRF1 and 
MAFbx contain glucocorticoid response elements that enhance their expression in the presence 




Figure 7. Glucocorticoid receptor (GR) signaling. Following glucocorticoid binding, GR 
becomes phosphorylated and translocates to the nucleus where it may influence transcription of 









Chapter 2: Identification and Functional Analysis of Family with sequence similarity 83 D 
(Fam83d) in Skeletal Muscle  
 
Introduction 
Overview of Fam83d 
Fam83d is one of 8 members of a family of proteins related by a highly conserved domain of 
unknown function, DUF1669, found at the N-terminus of each protein (21). This group of 
proteins shares little homology outside of the DUF1669 region. Endogenous expression of this 
family of proteins varies across tissue types but all members have been shown to be upregulated 
in one or more tumor types (21). Indeed, several studies have examined the function of Fam83d 
in cancer, including its role in breast cancer (22, 23), hepatocellular carcinoma (24) (25) lung 
cancer (26, 27) ovarian cancer (28, 29) and colorectal cancer (30). While its precise role in 
oncogenesis remains unclear, previous studies have demonstrated its involvement in several cell 
signaling pathways involved in cell proliferation and differentiation, including the MAP kinase, 
AKT/mTOR, and Wnt/β-catenin signaling cascades (22, 23, 24, 25, 26, 27, 28, 29, 30). 
 
Materials and Methods 
 
Cell Culture 
The C2C12 immortalized mouse myoblast cell line was obtained from the American Type Culture 
Collection (Manassas, VA) and maintained in DMEM (Life 163 Technologies, Grand Island, 
NY) supplemented with 10% fetal bovine serum (FBS) (GE164 Healthcare HyClone 
Laboratories, Logan, UT), non-essential amino acids, gentamicin, penicillin and streptomycin 
(all from Life Technologies, Grand Island, NY).  Cells were grown in a humidified chamber at 
37⁰C at 5% CO2. Cells were switched to DMEM supplemented with 2% FBS, non-essential 
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amino acids, gentamicin, penicillin and streptomycin 48 hours post plating to stimulated 
myotubes differentiation. 
 
RNA Isolation and cDNA synthesis  
Total RNA was isolated from C2C12 myoblast cells using the RNeasy Mini Kit (Qiagen, 
Valencia, CA) according to the manufacturer's protocol. Purified RNA (1µg) was reverse-
transcribed using Oligo-dT primers and Moloney Murine Leukemia Virus (M-MLV) Reverse 
Transcriptase according to the manufacturer's protocol (Life Technologies, Grand Island, NY) 
 
Amplification and cloning of the full length Fam83d cDNA 
For the amplification of Fam83d cDNA, gene-specific primer pairs were designed (Table 1) 
using the gene sequences from Mus musculus (GenBank accession number: NM_027975). PCR 
was performed according to the manufacturer's protocol (Life Technologies, Grand Island, NY) 
using Taq DNA polymerase, template prepared by reverse transcription of RNA isolated from 
C2C12 cells as described above and gene specific primer pairs (Table 1). Amplicons were cloned 
into the pGEM-T Easy vector (Promega, Madison, WI) according the manufacturer's protocol 
and sequenced using the Big Dye Sanger terminator sequencing method (Eurofins MWG 
Operon, Huntsville, AL) to confirm amplification of the expected target and the absence of 
mutations. The Fam83d cDNA was sub-cloned into the Xho1 and Xba1 restriction sites of 
pcDNA3.1 (+) (Life Technologies, Grand Island, NY) and sequenced to confirm correct 
orientation. The Fam83d cDNA was also sub-cloned into the Xho1 and Xba1 restriction sites of 
the pEGFP-C3 expression plasmid (Clontech, Mountain View, CA) and sequenced to confirm 
correct orientation and in frame fusion with GFP. The Fam83d cDNA fused to myc and DDDDK 
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tags in the PS100001 vector was purchased from OriGene Technologies (Rockville, MD) catalog 
number MR209141.  
 
Promoter cloning of the Fam83d gene 
For the amplification of the proximal regulatory region of Fam83d, genomic DNA was isolated 
from C2C12 cells using the DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA) according to 
the manufacturer's protocol. PCR was performed using Fam83d promoter region-specific primer 
pairs (Table 1) developed using mouse genomic sequences obtained from the Ensembl database 
(www.ensembl.org). PCR reactions were performed using Taq DNA polymerase and genomic 
mouse DNA according to the manufacturer's protocol (Life Technologies, Grand Island, NY). 
The PCR amplicons were cloned into the pGEM-T Easy vector (Promega, Madison, WI) 
according to the manufacturer's protocol and sequenced to confirm amplification of the predicted 
target region and the absence of mutations. The Fam83d promoter fragments (~500 and ~1000 
base pairs) were sub-cloned into the HindIII and Xho I sites of the pSEAP2-Basic reporter 
plasmid (Clontech, Mountain View, CA) to create the pSEAP-Fam83d-Pro500 and the pSEAP-
Fam83d-Pro1000 reporter plasmids and sequenced to confirm correct orientation. 
 
Site-directed mutagenesis  
The putative phospholipase D-like catalytic domain sequence located in exon 3 of Fam83d was 
mutated (H239N and K241Q) using the primer pairs listed in Table 1. The Fam83d-F280A 
mutant was generated using the primers listed in Table 1. The QuikChange II Site Directed 
Mutagenesis protocol utilizing PfuTurbo DNA polymerase was performed according to the 
manufacturer's protocol (Agilent Technologies, Santa Clara, CA). The mutagenesis PCR 
14 
 
reactions were digested with DpnI (New England BioLabs, Ipswich, MA) and then transformed 
into heat competent DH5α E.coli cells (Life Technologies, Grand Island, NY). Clones were 
isolated and plasmids were purified via alcohol precipitation and sequenced to confirm 
successful mutation of the phospholipase D-like domain catalytic pocket. 
 
Transfections 
C2C12 myoblast cells were plated into 12 well plates at a density of 75,000 cells/well with 
DMEM + 10% FBS (proliferation media) and cultured overnight. All conditions assessed were 
conducted in triplicate. Transfections were performed utilizing Turbofect Transfection Reagent 
(Thermo Scientific, Rockford, IL) following manufacturer protocol. One hour prior to 
transfection, media was refreshed and 1 μg of total DNA (250 ng/well of reporter plasmid, 125 
ng/well of β -galactosidase (β-gal) as the internal control plasmid, and empty pBluescript vector 
as filler DNA to 1 μg DNA/well) was allowed to complex with transfection reagent for 20 
minutes prior to overlaying the cells. Following 24-hour incubation with the transfection 
reaction, the proliferation media was replaced with differentiation media (DMEM + 2% FBS) 
and incubated for an additional 24-72 hours until reporter assays were performed.  
 
Reporter gene assay 
Growth media was collected from C2C12 mouse myoblasts at 24–72 hr after the switch to 
differentiation media post transfection and tested for SEAP levels using the Phospha‐Light SEAP 
Reporter Gene Assay Kit and following the manufacturer’s instructions (Life Technologies, 
Grand Island, NY). The level of SEAP generated luminescence was assessed with a Synergy 2 
microplate reader programmed for an endpoint read and a 2 s integration time. At the conclusion 
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of the experiment, cells were lysed with Passive Lysis Buffer (Promega, Madison, WI), lysates 
were centrifuged to clear cell debris and assessed for β‐galactosidase (β‐gal) activity. The SEAP 
activity numbers were corrected with β‐gal activity numbers to adjust for any variation in 
transfection levels between wells. 
 
Bioinformatic analysis of Fam83d 
DNA sequences corresponding to the promoter regions of human, rat, and mouse Fam83d 
(Ensembl Transcript ID: ENST00000619850.2, ENSRNOT00000021308.4, and 
ENSMUST00000029183.2, respectively) starting at ‐2000 and including the first exon were 
taken from the Ensembl database (www.ensembl.org) and analyzed using the Clustal Omega 
multiple sequence alignment tool available on the EMBL‐EBI website 
(https://www.ebi.ac.uk/Tools/msa/clustalo/). The Clustal Omega alignment data was then 
analyzed using Boxshade version 3.21 (http://www.ch.embnet.org/software/BOX_form.html) 
that is available on the ExPASy (www.expasy.org) website. The polypeptide sequences for 
human, mouse, and rat Fam83d were also downloaded from Ensembl and aligned using the 




Total RNA was isolated from proliferating and differentiated C2C12 cells as described above. 
Purified total RNA (1.0 μg) was reverse‐transcribed using the iScript cDNA Synthesis Kit 
according to the manufacturer’s protocol (Bio‐ Rad, Hercules, CA). cDNA amplification was 
conducted using the iTaq Universal SYBR Green Reaction Supermix and gene specific primers 
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(Table 1) according to the manufacturer’s protocol (Bio‐Rad, Hercules, CA) and the CFX 
Connect Real‐Time PCR Detection System (Bio‐Rad, Hercules, CA) was used to analyze 
quantitative gene expression of Fam83d at PD2, DD2 and DD7. Each timepoint was performed 
in biological triplicates, each individual biological replicate was used for cDNA synthesis in 
duplicate, and each cDNA synthesis replicate plated and analyzed in technical triplicates (three 
biological replicates × two cDNA synthesis replicates × three technical replicates = 18 individual 
reads per biological sample) and the experiment was repeated at least twice. Relative gene 
expression was calculated using the 2−ΔΔCt Livak method and GAPDH as the reference gene. 
 
Protein purification and Western blot analysis  
C2C12 cells were cultured in 10 cm culture dishes and Fam83d was exogenously expressed by 
transfecting the cells with the PS100001‐Fam83d-myc-DDK or pcDNA3.1-Fam83d expression 
plasmid 24 h post‐plating. The Fam83d overexpression time course was collected by harvesting 
cells 48 h post‐plating (PD2), as well as cells cultured for an additional 1,3 or 5 days in 
differentiation media (DD1, DD3, DD5). The collected cells were spun down and kept at −80°C 
until cell homogenization and protein isolation was performed. 
 
The harvested cells were incubated on ice for 30 min, with agitation every 10 minutes, in 
Universal Lysis Buffer (50mM Tris, pH 7.5, 150mM NaCl, 50mM NaF, 0.5% NP‐40), plus 
additions (1mM PMSF, 1mM DTT, 10mM β-glycerophosphate, 2mM sodium molbydate, and a 
protease inhibitor cocktail; ULB(+)). Cell homogenates were centrifuged to clear cellular debris 
and protein concentrations were determined using the Quick Start Bradford 1× Dye Reagent 




Western blots were conducted using 75-100 μg of protein on a 10% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis denaturing gel and then transferring overnight to 
polyvinylidene fluoride membrane (EMD Millipore, Billerica, MA). Membranes were stained 
with Ponceau S to visualize equal protein loading and successful transfer and then incubated with 
blocking solution (5% w/v dry milk in tris‐buffered saline with 0.05% Tween‐20). Western blots 
were probed with anti-Fam83d (gift from Dr. Gopal Sapkota, University of Dundee, United 
Kingdom), anti-myosin heavy chain (MYH1/2/4/6; sc-32732; Santa Cruz Biotechnology Dallas, 
TX), anti-myogenin (F5D; sc-12732; Santa Cruz Biotechnology, Dallas, TX), anti-p-ERK (E4; 
sc-7383; Santa Cruz Biotechnology, Dallas, TX), anti-ERK1 (K-23; sc-94; Santa Cruz 
Biotechnology, Dallas, TX), anti-Fbxw7 (28424-1-AP; ProteinTech, Rosemont, IL), anti-
CSNK1α1 (55192-1-AP; ProteinTech, Rosemont, IL), anti-MEK1/2 (11049-1-AP; ProteinTech, 
Rosemont, IL), anti- Calcoco1 (19843-1-AP; ProteinTech, Rosemont, IL), anti-HMMR (15820-
1-AP; ProteinTech, Rosemont, IL), anti-AKT-phospho-S473 (66444-1-lg; ProteinTech, 
Rosemont, IL). Anti-AKT (60203-2-lg; ProteinTech, Rosemont, IL), anti-phospho-mTOR-
Ser2448 (D9C2; #5536; Cell Signaling Technology, Danvers, MA), anti-phospho-
mTORSer2481 (#2974; Cell Signaling Technology, Danvers, MA), antiphospho-MEK1/2 
(9154T; Cell Signaling Technology, Danvers, MA), anti-phospho-GSK-3β (5558 T; Cell 
Signaling Technology, Danvers, MA), anti- GSK-3β (22104–1-AP; ProteinTech, Rosemont, IL), 
antimTOR (66888–1-lg; ProteinTech, Rosemont, IL) anti-myc (60003–2-lg; ProteinTech, 
Rosemont, IL), anti-DDDDK (FLAG equivalent) (20543–1- AP; ProteinTech, Rosemont, IL) 
anti-GAPDH (60004–1-lg; ProteinTech, Rosemont, IL) and anti-α tubulin (DM1A; sc-32293; 
Santa Cruz Biotechnology, Dallas, TX) primary antibodies followed by probing with an 
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appropriate HRP-conjugated secondary antibody (Santa Cruz Biotechnology, Dallas, TX) (Table 
2). Western blots were visualized using ECL substrate according to the manufacturer's 
instructions (Pierce/Thermo Fisher Scientific, Rockford, IL). PVDF membranes were stripped by 
incubating for 20–30 min in stripping buffer (10%SDS, 0.5 M tris-HCl pH 6.8 and β-
mercaptoethanol) at 50 °C, and then blocked, re-probed, and visualized as described above. 
Western blot band intensity quantifications were conducted using the open access ImageJ 
software. 
 
Confocal Fluorescence Microscopy 
C2C12 cells were plated using Cellvis (Sunnyvale, CA) 35mm glass bottom dishes and 
transfected 24 h after cells were plated with either the pEGFP‐C3 or pEGFP‐Fam83d plasmids 
duplexed with TurboFect Reagent (Thermo Fisher Scientific, Rockford, IL) as per 
manufacturer’s instructions. Before imaging, the cells were washed with phosphate buffered 
saline, fixed with paraformaldehyde, dissolved in sodium cacodylate, and stained with DRAQ5 
fluorescent DNA dye (Biostatus, Leicestershire, UK). The images were acquired using an 
Olympus Fluoview FV‐1000 confocal fluorescent microscope equipped with Super Apochromat 
UPLSAPO 20X and Super Apochromat UPLSAPO 60XW objectives. Open access ImageJ 
software combined with the Open Microscopy Environment Bio‐Formats plugin was used to 
analyze, merge, and save all images. 
 
Co-immunoprecipitation 
C2C12 cells were grown in 10% FBS DMEM media and transfected with Fam83d-myc-DDK 
expression plasmid and harvested 24 hours post transfection. Cells were lysed on ice for 30 
19 
 
minutes in ULB(+) (50mM Tris, pH 7.5, 150mM NaCl, 50mM NaF, 0.5% NP-40, 1mM PMSF, 
1mM DTT, 10mM β-glycerophosphate, 2mM sodium molbydate and a protease inhibitor 
cocktail). Protein was isolated by centrifugation and protein concentrations were quantified using 
the Quick Start Bradford 1X Dye Reagent (Bio-Rad, Hercules, CA) according to the 
manufacturer’s protocol. 500μg protein was diluted in ULB and precleared with protein A/G 
agarose beads (Pierce/Thermo Scientific, Rockford, IL) for 1 hour at 4°C with constant end-
over-end rotation. Beads were cleared from solution via centrifugation and the supernatant was 
incubated with 2μg anti-myc (60003-2-lg; Proteintech, 318 Rosemont, IL) antibody for 4 hours 
at 4°C with constant end-over-end rotation. Protein A/G agarose beads were added to solution 
and incubation was continued for 6 additional hours. Beads were cleared from solution via 
centrifugation and pelleted beads were washed 3X with ULB, and then boiled for 5 mins at 
95°C. 50μg of protein lysate was used for input control and SDS-PAGE was performed. 
Separated proteins were then transferred to a PVDF membrane and probed using the antibodies 
described above.  
 
Statistics 
Data are presented as the mean ± standard deviation (SD). Statistical analysis was conducted 
using a two-tailed t-test and a difference was considered statistically significant at a P value < 
0.05. 
 
Table 1. List of primers used in the Fam83d study 













Table 2.  List of antibodies used in the Fam83d study 
Antibody Source Catalog # Dilution 
anti-Fam83d University of Dundee, Scotland    WB: 1:500 
anti-Calcoco1 ProteinTech, Rosemont, IL 19843-1-AP WB: 1:2000 
anti-myc ProteinTech, Rosemont, IL 60003-2-lg  WB: 1:2000 
 IF: 1:50 
anti-α-tubulin Santa Cruz Biotechnology, Dallas, TX sc-32293  WB: 1:1000 
anti-Myosin Heavy 
Chain (MYH1/2/4/6) 
Santa Cruz Biotechnology, Dallas, TX sc-32732  WB: 1:1000 
anti-myogenin Santa Cruz Biotechnology, Dallas, TX sc-12732  WB: 1:1000 
anti-GAPDH ProteinTech, Rosemont, IL 60004-1-lg  WB: 1:5000 
anti-phospho-ERK Santa Cruz Biotechnology, Dallas, TX sc-7383 WB: 1:1000 
anti-ERK Santa Cruz Biotechnology, Dallas, TX sc-94  WB: 1:1000 
anti-phospho-MEK1/2 
(Ser217/221) 
Cell Signaling Technology, Danvers, MA 9154 WB: 1:2000 
anti-MEK1/2 ProteinTech, Rosemont, IL 11049-1-AP WB: 1:5000 
anti-Akt1-phospho-
S473 
ProteinTech, Rosemont, IL 66444-I-lg WB: 1:2000 
anti-Akt ProteinTech, Rosemont, IL 60203-2-lg  WB: 1:5000 
anti-phospho-mTOR-
Ser2448 
Cell Signaling Technology, Danvers, MA 5536  WB: 1:2000 
anti-mTOR ProteinTech, Rosemont, IL 66888-1-lg WB: 1:10000 
anti-phospho-GSK3β 
(Ser9) 
Cell Signaling Technology, Danvers, MA 5558 WB: 1:1000 
anti-GSK3β ProteinTech, Rosemont, IL 22104-1-AP WB: 1:2000 
anti-CSNK1A1 ProteinTech, Rosemont, IL 55192-1-AP WB: 1:2000 
anti-FBXW7 ProteinTech, Rosemont, IL 28424-1-AP WB: 1:5000 
anti-HHMR ProteinTech, Rosemont, IL 15820-1-AP  WB: 1:1000 
anti-DDK ProteinTech, Rosemont, IL 20543-1-AP  WB: 1:5000 
Mouse anti-rabbit IgG-
HRP 
Santa Cruz Biotechnology, Dallas, TX sc-2357 WB: 1:5000 
Rabbit anti-mouse IgG-
HRP (H+L) 
Thermo Scientific, Rockford, IL PI31450 WB: 1:5000 
Donkey anti-Sheep 
IgG-HRP (H+L) 





Goat anti-mouse IgG 
(H+L), FITC conjugate 








Fam83d is upregulated during neurogenic skeletal muscle atrophy  
RNA was isolated from control and denervated mouse gastrocnemius and soleus muscles and an 
Illumina mouse-6 v1.1 microarray was performed at 3 days and 14 days post denervation as 
previously described (5). Analysis of the microarray data submitted to the NCBI Gene 
Expression Omnibus (GEO) revealed a significant number of genes that show differential 
expression patterns in response to neurogenic muscle atrophy (5). Many of these genes have not 
previously been implicated in atrophy and have not been characterized in skeletal muscle. 
Fam83d shows low basal levels of expression in control gastrocnemius and soleus muscles and 
there was no significant difference in expression between control and denervated tissue at 3 days 
post-denervation; however, Fam83d was shown to be significantly upregulated by day 14 post-
denervation compared to control muscles (Fig. 8A). Fam83d is found on chromosome 2 in mice 
and is composed of four exons and three introns (Fig. 8B). The Fam83d gene locus shows 
architectural conservation between mouse and human and lies immediately downstream of 







Figure 8. Fam83d is upregulated during neurogenic atrophy. (A) Whole genome expression 
analysis was conducted on triceps surae muscle from wild-type (WT) mice after 3 days (3D) and 
14 days (14D) of denervation. Each condition represents the average expression from three 
animals and error bars represent ± SD. White bars, controls (Con); black bars, denervated (Den). 
Significant difference between denervated mice and control mice in the same group (**:P < .01). 
(B) Schematic of the Fam83d transcript in mouse. Darkened rectangles represent the exons 
containing the translated region, open rectangles represent exons containing the untranslated 
regions, and the lines connecting these rectangles represent introns. (C) Schematic of the mouse 
and human Fam83d gene loci on Chromosomes 2 and 20, respectively and the relative positions 
of adjacent genes.  
 
 
Fam83d is expressed during muscle cell proliferation but is rapidly degraded as cells 
differentiate 
To measure the transcriptional activity of Fam83d, total RNA was harvested from C2C12 mouse 
myoblasts during proliferation (PD2), as well as, from myotubes at early (DD2) and late (DD7) 
differentiation timepoints. cDNA synthesized from isolated RNA was used to conduct RT-qPCR 
using Fam83d specific primers (Table 1). The qPCR analysis demonstrated that Fam83d mRNA 
levels are significantly higher during proliferation when compared to both early and late 
differentiation timepoints (Fig. 9A). To validate the ability of a Fam83d antibody, generously 
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provided by Dr. Gopal Sapkota at the University of Dundee, United Kingdom, to detect mouse 
Fam83d, NIH3T3 cells were transfected with either a pcDNA3-Fam83d or pEGFP-Fam83d 
expression plasmid. Protein homogenates isolated from control cells and transfected cells were 
then analyzed by Western blot and the Fam83d antibody was able to successfully detect both the 
untagged and GFP-tagged Fam83d proteins (Fig. 9B). Protein homogenates from C2C12 cells 
isolated from proliferating myoblasts (PD2) and cells differentiated for 1, 3, and 5 days were 
analyzed by Western blot using the validated anti-Fam83d antibody to assess endogenous 
Fam83d protein levels. In agreement with the qPCR data, Western blot analysis revealed that 
Fam83d protein levels are higher during proliferation and then rapidly decrease as muscle cells 
differentiate (Fig. 9C). Myosin Heavy Chain (MyHC) was analyzed as a marker of muscle cell 
differentiation, Calcoco1 was used as a control for protein stability during differentiation, and α-
tubulin was used as a loading control. 
 
To determine if this decrease in protein level was due to degradation through the 26S proteasome 
pathway, C2C12 cells were transfected with a Fam83d-myc expression plasmid and treated with 
increasing concentrations of the proteasome inhibitor MG132. Cells were harvested 12 h post-
MG132 treatment and protein lysates were analyzed by Western blot. The levels of myc-tagged 
Fam83d were found to be much higher at differentiation day one compared to DMSO treated 






Figure 9. Fam83d expression in mouse myoblasts. (A) Fam83d mRNA is expressed highly 
during proliferation and then decreases significantly during differentiation. Quantitative 
polymerase chain reaction (qPCR) utilizing cDNA generated from RNA isolated from C2C12 
cells harvested at proliferation day 2 (PD2), differentiation day 2 (DD2) and differentiation day 7 
(DD7). Cells were maintained in proliferation media (10% serum) and harvested at 2 days post-
plating and the remaining cells were switched to differentiation media (2% serum) and harvested 
at 2- and 7-days post-media change. Significant difference between Fam83d expression in 
differentiated cells compared to Fam83d expression in proliferating cells (*:P < .05, **:P < .01). 
(B) Validation of a Fam83d antibody to detect murine Fam83d using protein lysates from 
NIH3T3 cells ectopically expressing mouse Fam83d. NIH3T3 cells were transiently transfected 
with pcDNA3-Fam83d, or pEGFP-Fam83d and 25 μg, 50 μg or 75 μg of protein lysate was 
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loaded and analyzed by Western blot. (C) Western blot analysis was performed with the 
validated Fam83d antibody using protein homogenates from proliferating [P] and differentiated 
[D] C2C12 cells harvested over a 5-day differentiation time course to assess endogenous Fam83d 
protein levels. Cells were maintained in proliferation media (10% serum) and harvested at 2-days 
post-plating and the remaining cells were then switched to differentiation media (2% serum) and 
harvested at 1, 3, and 5 days post-media change. Myosin Heavy Chain (MyHC) was analyzed as 
a marker of differentiation, Calcoco1 was analyzed as a protein that is not affected by muscle 
cell differentiation, and α-tubulin was analyzed to confirm equal protein loading. (D) Western 
blot analysis using lysates from C2C12 cells transfected with a Fam8d3-myc-Flag expression 
plasmid, treated with MG132 (0.625, 1.25, and 2.5 μM), harvested after 1 day of differentiation, 
and probed using an anti-myc antibody. α-tubulin was analyzed to confirm equal protein loading. 
 
Fam83d Expression Is Regulated by Myogenic Regulatory Factors 
To gain insight into how Fam83d is regulated transcriptionally in muscle cells, 416 and 785 base 
pairs of the promoter were amplified using the primers listed in Table 1. The fragments were 
then fused to a secreted alkaline phosphatase (SEAP) reporter plasmid to create the pSEAP-
Fam83d-Pro416 and pSEAP-Fam83d-Pro785 reporter constructs. The Fam83d reporter gene 
constructs were transfected into C2C12 mouse myoblasts and SEAP assays were performed 48 h 
after the switch to differentiation media. The 416 and 785 bp fragments both showed 
significantly higher expression compared to the empty plasmid alone (Fig. 10A). Bioinformatic 
analysis of the promoter region of Fam83d revealed three canonical E-Box elements within the 
first 400 bps upstream of the start of transcription (Fig. 10B). Myogenic regulatory factors, such 
as MyoD, are known to regulate gene transcription through interaction with E-box consensus 
elements (5′- CANNTG-3′) found in the promotors of muscle-specific genes. Therefore, to 
determine if the Fam83d reporter genes are responsive to ectopic expression of MyoD, cells were 
transfected with a MyoD expression plasmid in combination with the reporter gene constructs. 
Overexpression of MyoD significantly repressed the transcriptional activity of both the pSEAP-








Figure 10. Cloning and analysis of the proximal regulatory region of the Fam83d gene locus. 
(A) C2C12 myoblasts were transfected with either an empty reporter plasmid or reporter plasmids 
containing 416 bp or 785 bp of the Fam83d promoter fused to the Secreted Alkaline Phosphatase 
(SEAP) reporter gene. Each condition was performed in triplicate and each experiment was 
repeated at least three times (n = 3). The graphs are of a representative experiment and values 
correspond to the mean relative light unit (RLU) values ±SD. Significant difference between the 
empty control reporter plasmid (pSEAP2-Basic) and the pSEAP2-Fam83d reporter constructs, 
(*: P < .0001). (B) Schematic and sequence alignment of the Fam83d regulatory region. 
Promoter sequences from mouse, rat, and human Fam83d (2000 base pairs upstream of the 
transcription start site (+1) through the first exon) were downloaded from the Ensembl database 
(www.ensembl.org) and aligned using the ClustalW algorithm. Approximate positions of 
putative transcription factor binding sites are indicated in the schematic of the Fam83d 
regulatory region at the top. Putative TFIIB Response Element (BRE) 5′-
(G/C)(G/C(G/A)CGCC-3′ (black trapezoids) and putative consensus E-box elements 5′-
CANNTG-3′ (checkered diamond and dotted triangle) are indicated. N represents any nucleotide. 
Conserved nucleotides are highlighted in black, transitions are highlighted in gray, and 
transversions are highlighted in white. C2C12 myoblasts were transfected with either the (C) 
pSEAP2-Fam83d-Pro416 reporter or the (D) pSEAP2-Fam83d-Pro785 reporter with or without a 
MyoD expression plasmid. The media was then assayed for SEAP activity 48 h (DD2) following 
the switch to differentiation media and SEAP numbers were normalized to β-galactosidase 
activity to correct for variations in transfection efficiency. Each condition was performed in 
triplicate and each experiment was repeated at least three times (n = 3). The graphs are of a 
representative experiment and values correspond to the mean relative light unit (RLU) values 
±SD. Significant differences between the activities of the pSEAP2-Fam83d-Pro reporter 
constructs with and without MyoD ectopic expression, (**: P < .01). 
 
Subcellular localization of Fam83d 
The Fam83d gene is located on chromosome 2 in mouse and encodes a 585 amino acid 
polypeptide with a predicted molecular weight of approximately 56 kDa, although the observed 
molecular weight appears closer to 70 kDa (Fig. 9C). The Fam83d protein contains a 
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putative domain of unknown function (DUF) located at the N-terminus of the polypeptide 
(highlighted in red in the alignment), which is conserved among all members of the Fam83 
family (Fig. 11A). Further analysis utilizing the NCBI conserved domain database identified a 
putative phospholipase D-like (PLD-like) catalytic motif (highlighted in green in the alignment) 
within this DUF region (Fig. 11A). As this is the first study to describe Fam83d in skeletal 
muscle, there are no other reports describing its localization in muscle cells. Therefore, Fam83d 
was fused with GFP and the fusion protein was ectopically expressed in cultured myoblasts to 
determine subcellular localization by confocal fluorescent microscopy. C2C12 cells were 
transfected with either an empty GFP expression plasmid or a Fam83d-GFP expression plasmid 
and analyzed 24 h post-transfection. The control cells transfected with the empty GFP expression 
plasmid showed uniform GFP localization throughout the cell (Fig. 11B, Panels 1–3), while cells 
transfected with the Fam83d-GFP fusion plasmid showed accumulation in puncta located in the 
cytoplasm of cultured myoblasts (Fig. 11B, Panels 4–12). Since GFP has been known to affect 
localization of proteins it is fused with, we also overexpressed myc-tagged Fam83d in C2C12 
myoblasts and performed immunofluorescence using an anti-myc antibody and a FITC-
conjugated secondary and found that the localization pattern matched the GFP-Fam83d 




















Figure 11. Fam83d localizes to the cytoplasm of myoblast cells. (A) Sequences of the mouse, 
rat, and human Fam83d protein were downloaded from the Ensembl database and aligned using 
the ClustalW2 algorithm. Approximate position of the domain of unknown function 1669 
(DUF1669) is highlighted in red and the putative phospholipase D-like motif catalytic pocket is 
highlighted in greed in the alignment. (B) Proliferating C2C12 cells (PD2) transfected with the 
empty pEGFP-C3 expression vector were imaged at 20× (Panels 1–3) and uniform cellular 
localization of GFP was observed. Representative C2C12 cells transfected with a pEGFP-Fam83d 
expression plasmid were imaged at proliferation day 2 (PD2) at 20× (Panels 4–6), 60× (Panels 
7–9, and 100× (Panels 10–12) and punctate cytoplasmic fluorescence was observed. Draq5, a 
cell permeable fluorescent DNA dye, was used to visualize cell nuclei. (C) Immunofluorescent 
detection of Fam83d-myc-Flag was performed using C2C12 myoblast cells. C2C12 cells were 
transfected with a Fam83d-myc-Flag expression plasmid and then incubated with a myc primary 
antibody and a FITC-conjugated secondary antibody revealing punctate cytoplasmic 
fluorescence at 60× (Panels 1–3) and 100× (Panels 4–9) magnification. Draq5, a cell permeable 




Ectopic expression of Fam83d inhibits muscle cell differentiation 
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To evaluate if Fam83d impacts muscle cell differentiation, C2C12 cells were transfected with a 
myc-tagged Fam83d expression plasmid. Cells were then harvested over a time course that 
included 2 days of proliferation (PD2) and 1, 3 and 5 days of differentiation (DD1, DD3 
and DD5, respectively). Protein was isolated from cells and evaluated for the level of expression 
of the canonical makers of muscle cell differentiation, skeletal muscle myosin heavy chain 
(MyHC) and myogenin. Western blot analysis showed significantly lower levels of both 
myogenin and MyHC at all differentiation time points (Fig. 12A). To quantify the amount of 
inhibition, Fam83d was overexpressed in biological quadruplicates and harvested at 3 days of 
differentiation. Lysates were evaluated by Western blot and myogenin and MyHC expression 
levels and were found to be significantly repressed in lysates isolated from cells ectopically 
expressing Fam83d (Fig. 12B and C). Fam83d protein levels were analyzed to confirm 
overexpression and GAPDH was analyzed to confirm equal loading and to correct for variations 





Figure 12. Ectopic expression of Fam83d attenuates muscle cell differentiation. C2C12 cells were 
transfected with a Fam83d-myc-Flag expression plasmid or mock transfected followed by 
Western blot analysis. (A) Western blot analysis of Fam83d, Myosin Heavy Chain (MyHC), and 
myogenin using protein homogenates from proliferating (PD) and differentiated (DD) C2C12 
cells harvested over a 5-day differentiation time course. Cells were maintained in proliferation 
media (10% serum) and harvested 2 days post-plating and the remaining cells were then 
switched to differentiation media (2% serum) and harvested at 1, 3 and 5-days post-media 
change. GAPDH was analyzed to confirm equal protein loading. The experiments were repeated 
at least three times and the Western blots shown are representative examples of the results 
obtained. (B) C2C12 cells were transfected with a Fam83d-myc-Flag expression plasmid or mock 
transfected in biological quadruplicates and cell lysates were then analyzed by Western blot for 
Fam83d, MyHC, and myogenin. Cells were maintained in proliferation media then switched to 
differentiation media (2% serum) for 3 days. GAPDH and α-tubulin was analyzed to confirm 
equal protein loading. The experiment was performed in quadruplicate (n = 4), repeated at least 
three times, and the blots shown are representative examples of the results obtained. (C) 
Quantification of the Western blot band intensities for Fam83d, MyHC, and myogenin. Relative 
intensity of each band was corrected to either GAPDH (shown) or α-tubulin band intensities for 
each corresponding biological replicate. Significant differences between control cells compared 
to cells ectopically expressing Fam83d-myc-Flag, (****: P < .0001). 
 
Fam83d overexpression attenuates MAP kinase signaling 
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To determine if Fam83d overexpression impacts MAP kinase signaling, C2C12 cells were 
transfected with a pSEAP-Pro-AP-1 reporter construct in combination with increasing 
concentrations of a wild-type Fam83d-myc-Flag expression plasmid (Fam83d-myc-Flag WT). 
Growth media was sampled 24 h post-transfection to evaluate SEAP levels in proliferating 
myoblasts and the AP-1 reporter showed significant activity at this timepoint in control cells, 
while Fam83d overexpression significantly reduced reporter activity in a dose-dependent manner 
(Fig. 13A). To confirm that Fam83d ectopic expression negatively regulates the MAP kinase 
signaling pathway, C2C12 mouse cells were harvested over a differentiation time course, as well 
as, in biological quadruplicate at differentiation day 3 (DD3) as described above. Protein 
homogenates from cells ectopically expressing Fam83d were evaluated by Western blot to assess 
the effect that overexpression has on MAP kinase signaling. ERK1/2 phosphorylation levels 
decreased significantly in lysates isolated from cells overexpressing Fam83d at all differentiation 
time points assessed (Fig. 13B-D). To determine if Fam83d functions upstream of ERK1/2 in the 
MAP kinase signaling cascade, MEK1/2 and phosphorylated MEK1/2 levels were also evaluated 
by Western blot. Overexpression of Fam83d did not significant effect the level of whole 
MEK1/2 protein, but did show a small but significant inhibition of the phosphorylation status of 
MEK1/2 (p- MEK), suggesting that Fam83d likely influences MAP kinase signaling 
predominantly at the level of ERK1/2 in muscle cells (Fig. 13B-D). To investigate if a putative 
phospholipase D-like (PLD-like) motif is necessary for Fam83d inhibition of MAP kinase 
signaling, site-directed mutagenesis was used to modify two residues in the predicted catalytic 
pocket to create the Fam83d-H239N/K241Q double mutant. Interestingly, in contrast to wild-
type Fam83d, overexpression of the Fam83d PLD-like motif mutant did not significantly inhibit 
the AP-1 reporter activity (Fig. 13A). To confirm that Fam83d-H293N/K241Q ectopic 
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expression does not negatively regulate the MAP kinase signaling pathway to the same level as 
wild-type Fam83d, C2C12 cells were harvested in biological quadruplicate at DD3. Western blot 
analysis showed that overexpression of the Fam83d phospholipase D-like motif mutant had no 
significant effect on ERK1/2 protein or phosphorylation levels, in contrast to wild-type Fam83d 











Figure 13. Fam83d overexpression inhibits AP-1 reporter activity and MAP kinase signaling. 
(A) C2C12 cells were transfected with an AP-1 reporter plasmid and either a wild-type Fam83d or 
Fam83d-H239N/K241Q double mutant expression plasmid. The media was then assayed for 
SEAP activity 48 h (DD2) following the switch to differentiation media and SEAP numbers were 
normalized to β-galactosidase activity to correct for variations in transfection efficiency. Each 
condition was performed in triplicate and each experiment was repeated at least three times (n = 
3). The graphs are of a representative experiment and values correspond to the mean relative 
light unit (RLU) values ±SD. Significant differences between the activities of the pSEAP2-AP-1-
Pro reporter construct alone and in combination with Fam83d-WT or Fam83d-H239N/K241Q 
ectopic expression, (**: P < .01, ***: P < .001). (B) C2C12 cells were transfected with a Fam83d-
myc-Flag expression plasmid or mock transfected followed by Western blot analysis. Cells were 
maintained in proliferation media (10% serum) and harvested 2 days post-plating and the 
remaining cells were then switched to differentiation media (2% serum) and harvested 1, 3, and 5 
days post-media change. Western blot analysis of phosphorylated-ERK1/2 (p-ERK1/2), pan-
ERK1/2 (ERK1/2), phosphorylated-MEK1/2 (p-MEK1/2), and pan-MEK1/2 (MEK1/2) using 
protein homogenates from proliferating (PD2) and differentiated C2C12 cells. The experiments 
were repeated at least three times (n = 3) and the Western blots shown are representative 
examples of the results obtained. (C) C2C12 cells were transfected with a Fam83d-myc-Flag WT 
expression plasmid or mock transfected in biological quadruplicates. Western blot analysis of 
phosphorylated ERK1/2 (p-ERK1/2), pan-ERK1/2 (ERK1/2), phosphorylated-MEK1/2 (p-
MEK1/2), and pan-MEK1/2 (MEK1/2) using protein homogenates from C2C12 cells 
differentiated for 3 days. The experiment was performed in quadruplicate (n = 4), repeated at 
least three times, and the blots shown are representative examples of the results obtained. (D) 
Quantification of the Western blot band intensities were measured for pan-ERK1/2 and pan-
MEK1/2 protein levels, as well as, the phospho-ERK1/2 to pan-ERK1/2 ratio and the phospho-
MEK1/2 to pan-MEK ratios. Significant differences between control cells compared to cells 
ectopically expressing Fam83d, (*: P < .05, **: P < .01, N.S. = not significant). (E) C2C12 cells 
were transfected with a Fam83d-H239N/K241Q expression plasmid or mock transfected in 
biological quadruplicates. Western blot analysis of Fam83d, phosphorylated-ERK1/2 (p-
ERK1/2), pan-ERK1/2 (ERK1/2), phosphorylated-MEK1/2 (p- MEK1/2), and pan-MEK1/2 
(MEK1/2) using protein homogenates from C2C12 cells differentiated for 3 days. The experiment 
was performed in quadruplicate (n=4), repeated at least three times, and the blots shown are 
representative examples of the results obtained. (F) Quantification of the Western blot band 
intensities were measured for pan-ERK1/2 and the phospho-ERK1/2 to pan-ERK1/2 ratio. (N.S. 




Fam83d overexpression attenuates AKT signaling 
The effect of Fam83d overexpression on AKT signaling was also evaluated by Western blot over 
a differentiation time course, as well as, in biological quadruplicate at DD3. Overexpression of 
Fam83d significantly reduced whole protein and phosphorylation levels of AKT at all time 
points assessed (Fig. 14A-D). To further evaluate the effect of Fam83d on the AKT signaling 
pathway, mTOR protein and phosphorylation levels were also investigated. Interestingly, at 3 
days of differentiation, Fam83d overexpression had no significant effect on total mTOR protein 
or phosphorylation of S2448, which is a primary target residue for AKT phosphorylation. GSK-
3β, another downstream target of AKT signaling, was also evaluated and no significant effect at 
the whole protein level was observed in response to ectopic expression of Fam83d, while a small 
but significant repression in phosphorylation levels in response to Fam83d overexpression was 






Figure 14. Ectopic expression of Fam83d inhibits AKT signaling in muscle cells. (A) C2C12 cells 
were transfected with a Fam83d-myc-Flag expression plasmid or mock transfected. Cells were 
maintained in proliferation media (10% serum) and harvested 2 days post-plating and the 
remaining cells were then switched to differentiation media (2% serum) and harvested 1, 3, and 5 
days post-media change. Western blot analysis of phosphorylated-AKT (p-AKT), pan-AKT 
(AKT), phosphorylated serine 2448-mTOR (p-S2448-mTOR), pan-mTOR (mTOR), 
phosphorylated-GSK-3β (p-GSK-3β), and pan-GSK-3β (GSK-3β) using protein homogenates 
from proliferating (PD2) and differentiated C2C12 cells. These experiments were repeated at least 
three times (n = 3) and the Western blots shown are representative examples of the results 
obtained. (B) C2C12 cells were transfected with a Fam83d-myc-Flag WT expression plasmid or 
mock transfected in biological quadruplicates. Western blot analysis of phosphorylated-AKT (p-
AKT), pan-AKT (AKT), phosphorylated serine 2448 mTOR (p-S2448-mTOR), pan-mTOR 
(mTOR), phosphorylated-GSK-3β (p-GSK-3β), and pan-GSK-3β (GSK-3β) using protein 
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homogenates from C2C12 cells differentiated for 3 days. The experiment was performed in 
quadruplicate (n =4), repeated at least three times, and the blots shown are representative 
examples of the results obtained. (C) Quantification of the Western blot band intensities were 
measured for AKT, mTOR, and GSK-3β. Relative intensity of each band was corrected to either 
GAPDH or α-tubulin band intensities for each corresponding biological replicate. Significant 
differences between control cells compared to cells ectopically expressing Fam83d-myc-Flag, (*: 
P < .05, N.S. = not significant). (D) Relative intensity of the phospho-AKT to pan-AKT ratio, the 
phospho-S2448-mTOR to pan-mTOR ratio, and the phospho-GSK-3β (p-GSK-3β) to pan-GSK-
3β (GSK-3β) ratio. Significant differences between control cells compared to cells ectopically 
expressing Fam83d-myc-Flag, (*: P < .05, **: P < .01, N.S. = not significant). 
 
 
Fam83d physically interacts with and destabilizes casein kinase 1α in muscle cells 
Previous studies have demonstrated that Fam83 family members interact with casein kinase 1α 
(CSNK1α1) and HMMR (31, 32, 33, 34).To investigate if these interactions occur in muscle 
cells, co-immunoprecipitation (co-IP) was performed using protein lysates isolated from C2C12 
myoblasts transfected with a Fam83d-myc-Flag expression plasmid and harvested 24 h post-
transfection. Immunoprecipitation of the Fam83d protein revealed a strong interaction with 
CSNK1α1 and HMMR (Fig. 15). To determine if the interactions between Fam83d and 
CSNK1α1 and Fam83d and HMMR are dependent on the putative phospholipase D-like (PLD) 
motif, lysates from C2C12 cells overexpressing the Fam83d-H239N/K241Q mutant protein were 
also used for co-IP. Interestingly, mutation of the PLD-like motif significantly impaired the 
Fam83d/CSNK1α1 interaction, but did not affect the Fam83d/HMMR interaction (Fig. 15). 
Fam83d has also been shown previously to associate with Fbxw7 in colorectal cancer (30) and 
breast cancer (22) but co-immunoprecipitation showed no evidence of a direct interaction 




Figure 15. Fam83d physically interacts with casein kinase 1α. Fam83d directly interacts with 
casein kinase Iα and HMMR but not Fbxw7 in muscle cells. Immunoprecipitation (IP) of 
Fam83d from control C2C12 cells and cells overexpressing wild-type Fam83d-myc- Flag or 
Fam83d-myc-Flag-H239N/K241Q double mutant followed by Western blotting for casein kinase 
Iα, Fbxw7, HMMR, or Fam83d-Flag (top four panels). Western blot analysis confirmed 
relatively equal casein kinase Iα, Fbxw7, HMMR, Fam83d, and GAPDH in cell lysates from 
control C2C12 cells and cells overexpressing Fam83d-WT or Fam83d-H239N/K241Q (bottom 
five panels).  
 
To further investigate the affect Fam83d might have on CSNK1α1, HMMR, and Fbxw7 stability, 
protein lysates from cells harvested over a differentiation time course and in biological 
quadruplicates at DD3 were evaluated by Western blot. Overexpression of Fam83d-WT 
significantly reduced CSNK1α1 protein levels at PD2 but did not appear to effect stability during 
differentiation (Fig. 16A-C). In contrast, Fbxw7 and HMMR protein levels showed significant 







Figure 16. Overexpression of Fam83d destabilizes casein kinase 1α. (A) C2C12 cells were 
transfected with a Fam83d-myc-Flag expression plasmid or mock transfected. Western blot 
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analysis of casein kinase Iα, Fbxw7, and HMMR using protein homogenates from proliferating 
(PD2) and differentiated (DD1, DD3, and DD5) C2C12 cells. The experiments were repeated at 
least three times (n = 3) and the Western blots shown are representative examples of the results 
obtained. GAPDH was analyzed to confirm equal protein loading. (B) C2C12 cells were 
transfected with a wild-type Fam83d-myc-Flag expression plasmid or mock transfected in 
biological quadruplicates. Western blot analysis of casein kinase Iα, Fbxw7, and HMMR using 
protein homogenates from C2C12 cells differentiated for 3 days. The experiment was performed 
in quadruplicate (n = 4), repeated at least three times, and the blots shown are representative 
examples of the results obtained. GAPDH was analyzed to confirm equal protein loading. (C) 
Quantification of the Western blot band intensities measured from part C. Significant differences 
between control cells and cells ectopically expressing Fam83d, (**: P < .01, ****: P < .0001, 
N.S. = not significant). 
 
To determine if the PLD-like motif plays a role in CSNK1α1, HMMR, and Fbxw7 protein 
stability, the Fam83d-H239N/K241Q mutant was overexpressed in cultured muscle cells and 
harvested in biological quadruplicates at DD3. In contrast to wild-type Fam83d, Fam83d-
H239N/ K241Q overexpression resulted in significantly elevated levels of CSNK1α1, while 
Fbxw7 levels remained unchanged compared to control cells (Fig.17A and B)). Furthermore, as 
described above, AKT protein levels were found to be significantly repressed in response to 
ectopic expression of wild-type Fam83d (Fig. 14B and C). Therefore, AKT protein levels were 
also assessed using lysates harvested from cells ectopically expressing the Fam83d double 
mutant and no significant change in expression of AKT was observed (Fig. 17A and B). 
Interestingly, HMMR protein levels were elevated in cells overexpressing either Fam83d-WT 
(Fig. 16B and C) or Fam83d-H239N/K241Q (Fig. 17A and B). These results suggest that the 
mechanism by which Fam83d affects CSNK1α1, AKT, and Fbxw7 protein stability may depend 
on the putative phospholipase D-like motif, while stabilization of HMMR may be independent of 





Figure 17. Fam83d effect on casein kinase 1α stability is PLD-like motif dependent. (A) C2C12 
cells were transfected with the Fam83d-H239N/K241Q double mutant expression plasmid or 
mock transfected in biological quadruplicates. Western blot analysis of casein kinase Iα, Fbxw7, 
HMMR, and AKT using protein homogenates from C2C12 cells differentiated for 3 days. The 
experiment was performed in quadruplicate (n = 4), repeated at least three times, and the blots 
shown are representative examples of the results obtained. GAPDH was analyzed to confirm 
equal protein loading. (B) Quantification of the Western blot band intensities measured from part 
A. Significant differences between control cells and cells ectopically expressing Fam83d-




Finally, to support the hypothesis that the putative PLD-like motif likely plays a role in 
CSNK1α1 stability and ERK1/2 phosphorylation levels, a second Fam83d mutant, Fam83d-
F280A, was generated. Mutation of F280 has previously been shown to abolish the Fam83d- 
CSNK1α1 interaction (32, 33). Co-immunoprecipitation assays demonstrate that the Fam83d-
F280A mutant has diminished CSNK1α1 binding ability in muscle cells (Fig. 18A). 
Furthermore, unlike the Fam83d PLD-like motif mutant, overexpression of the Fam83d-F280A 
mutant did not lead to increased levels of CSNK1α1 in differentiated C2C12 cells (Fig. 18B and 
C). Additionally, ectopic expression of the Fam83d-F280A mutant caused significant repression 
of ERK1/2 phosphorylation (Fig. 18B and C), which matches the results obtained for Fam83d-






Figure 18. Fam83d-F280A mutant inhibits ERK1/2 phosphorylation and does not destabilize 
casein kinase 1α. (A) Fam83d-F280A does not interact with casein kinase Iα. 
Immunoprecipitation (IP) of Fam83d from control C2C12 cells and cells overexpressing wild-
type Fam83d-myc-Flag, Fam83d-myc-Flag-H239N/K241Q double mutant, or Fam83d-myc-
Flag-F280A mutant followed by Western blotting for casein kinase Iα or Fam83d-Flag (top two 
panels). Western blot analysis confirmed relatively equal casein kinase Iα, Fam83d, and GAPDH 
in cell lysates from control C2C12 cells and cells overexpressing Fam83d-myc-Flag WT, 
Fam83d-myc-Flag-H239N/K241Q, or Fam83d-myc-Flag-F280A (bottom three panels). (B) 
C2C12 cells were transfected with a Fam83d-myc-Flag-F280A mutant expression plasmid or 
mock transfected in biological quadruplicates. Western blot analysis of Fam83d, phospho-
ERK1/2, pan-ERK1/2, CSNK1α1, HMMR, and AKT using protein homogenates from C2C12 
cells differentiated for 3 days (DD3). The experiment was performed in quadruplicate (n = 4), 
repeated at least three times, and the blots shown are representative examples of the results 
obtained. GAPDH was analyzed to confirm equal protein loading. (C) Quantification of the 
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Western blot band intensities measured from part B. Significant differences between control cells 
compared to cells ectopically expressing Fam83d-myc-Flag-F280A, (***: P < .001, ****: P < 
.0001, N.S. = not significant). 
 
Inhibition of ERK1/2 and MEK1/2 stabilizes Fam83d during muscle cell differentiation 
As noted above, ectopic expression of Fam83d in C2C12 results in a high level of expression 
during proliferation and then rapidly decreases as cells begin to differentiate (Fig. 9C and D). 
Since Fam83d inhibits the ERK1/2 branch of the MAP kinase signaling pathway, and inhibition 
of ERK1/2 or MEK1/2 causes pre-mature differentiation of C2C12 cells, we evaluated if 
inhibition of ERK1/2 or MEK1/2 using small molecule inhibitors might impact Fam83d stability 
during muscle cell differentiation. To answer this question, C2C12 cells were transfected with a 
Fam83d-myc-Flag expression plasmid and treated with increasing concentrations of either 
GSK1120212 (MEK inhibitor) or SCH772984 (ERK inhibitor) 24 h post-transfection and again 
at the switch to differentiation media. Cells were then harvested 24 h posttreatment and protein 
lysates were analyzed by Western blot. Fam83d protein levels were significantly elevated in 
response to both the MEK1/2 and ERK1/2 inhibitors (Fig. 19A-E). Furthermore, stabilization of 
Fam83d using the ERK1/2 and MEK1/2 inhibitors also resulted in significantly elevated levels 








Figure 19. Inhibition of the MAP kinase signaling pathway stabilizes Fam83D. (A) C2C12 cells 
were transfected with a wild-type Fam83d-myc-Flag expression plasmid and cells were then 
treated with either the MEK1/2 inhibitor GSK1120212 (2.5 μM, 5 μM or 10 μM) or the ERK1/2 
inhibitor SCH772984 (1 μM. 2 μM or 4 μM) or vehicle alone 24 h post-transfection. Western 
blot analysis of Fam83d-myc-Flag using protein homogenates from cells differentiated for 1 day. 
α-tubulin was analyzed to confirm equal protein loading. (B) C2C12 cells were transfected with a 
wild-type Fam83d-myc-Flag expression plasmid and then treated with either SCH772984 (4 μM) 
or vehicle alone 24 h post-transfection and differentiated for 1 day. Western blot analysis of 
Fam83d-myc-Flag, casein kinase Iα, and AKT using protein lysates from cells differentiated for 
49 
 
1 day. The experiment was performed in quadruplicate (n = 4), repeated at least three times, and 
the blots shown are representative examples of the results obtained. α-tubulin was analyzed to 
confirm equal protein loading. (C) Quantification of the Western blot band intensities measured 
from part B. Significant differences between control cells and cells treated with SCH772984, (*: 
P < .05, **: P < .01, ****: P < .0001). (D) C2C12 cells were transfected with a wild-type 
Fam83d-myc-Flag expression plasmid and then treated with either GSK1120212 (5 μM) or 
vehicle alone 24 h post-transfection and differentiated for 1 day. Western blot analysis of 
Fam83d-myc-Flag, casein kinase Iα, and AKT using protein lysates from cells differentiated for 
1 day. The experiment was performed in quadruplicate (n = 4), repeated at least three times, and 
the blots shown are representative examples of the results obtained. α-tubulin was analyzed to 
confirm equal protein loading. (E) Quantification of the Western blot band intensities measured 
from part D. Significant differences between control cells and cells treated with GSK1120212, 




Skeletal muscle is unique among body tissues due to its high degree of plasticity and its ability to 
regulate its size and mass (9, 35). Skeletal muscle mass is maintained by a balance between 
protein synthesis and protein degradation and when this balance is shifted toward protein 
degradation, atrophy occurs (35). This imbalance can be triggered by a wide range of 
physiological events including denervation, starvation, disease, disuse, and aging (9). While 
there has been much work focused on degradation pathways, such as the ubiquitin proteasome 
system, the molecular mechanisms that underly these disparate atrophy-inducing events remains 
unclear. Fam83d has been identified as a novel molecular component of the atrophy cascade as it 
is transcriptionally active in muscle and was found to be upregulated in response to neurogenic 
atrophy (5). Fam83d has been previously studied in a variety of cancer models but this is the first 
study to examine its role in muscle.  
 
To characterize the expression and regulation of Fam83d in muscle, qPCR was conducted using 
cDNA generated from C2C12 mouse myoblasts over a differentiation time course. These results 
showed that Fam83d is highly upregulated during myoblast proliferation and is significantly 
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down regulated as the cells proceed through differentiation. In addition, a Fam83d reporter gene 
was found to be highly active in proliferating muscle cells and was repressed by ectopic 
expression of MyoD, a myogenic regulator factor (MRFs) that is capable of binding canonical E-
box elements such as those found in the proximal promoter region of Fam83d. Muscle 
development is a highly ordered process controlled by a concert of myogenic regulatory factors 
being expressed at specific stages of muscle cell development (36). Myf5 is the first MRF to be 
expressed in satellite cells, which commits them to the muscle cell lineage. MyoD expression 
follows shortly thereafter, in a semi-redundant role, to further push cells toward muscle cell 
development. Finally, as MyoD expression rises in proliferating myoblasts myogenin and MRF4 
are transcriptionally activated, which subsequently promotes muscle cell differentiation and 
myotube formation (36). Therefore, the transcriptional repression of Fam83d during muscle 
differentiation is likely MRF-dependent and might be a necessary step in muscle development. In 
support of the qPCR data, endogenous Fam83d protein levels were found to decrease 
significantly as cultured muscle cells transitioned from proliferating myoblasts to differentiated 
myotubes.  
 
Ectopic expression of myc-tagged Fam83d fusion protein was also found to be highly expressed 
during proliferation and then rapidly turned over, which matches the endogenous Fam83d 
expression pattern in muscle cells. Furthermore, treatment with MG132 stabilized Fam83d 
expression during differentiation suggesting Fam83d is actively degraded by the 26S proteasome 
as muscle cell differentiation progresses. These findings together suggest that Fam83d may have 
a muscle-specific role with a narrow window of activity during the proliferative stage of muscle 
development and is then transcriptionally downregulated and 
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proteolytically degraded as cells enter differentiation. This is in agreement with previous 
findings in several models of cancer where Fam83d was found to be a cell-cycle related gene and 
alterations in its expression effected cell proliferation (22, 25, 29, 30, 31). Additionally, Fam83d 
has previously been shown to be co-expressed with several mitosis-related genes (37).  
 
To better understand the function of this gene in skeletal muscle, Fam83d was overexpressed and 
protein lysates were compared to those from control cells via Western blot. It was found that 
ectopic expression of Fam83d inhibited myogenic differentiation, as determined by significant 
decreases of both myogenin and myosin heavy chain at all time points of differentiation tested. It 
is important to note that C2C12 cells proliferate as myoblasts until they reach a confluent 
monolayer and then fuse and differentiate into multinucleated myotubes on the culture plate 
under reduced serum conditions. Therefore, if Fam83d were driving C2C12 cell proliferation as is 
observed in many cancer cell models, it would be expected that myoblasts overexpressing 
Fam83d would differentiate more quickly than cells not overexpressing Fam83d.  
 
Furthermore, signaling pathways involved in myogenesis have been extensively studied and it is 
well established that perturbations in these pathways can impair, delay or prevent muscle cell 
differentiation and tissue development (11) One such pathway is the mitogen-activated protein 
(MAP) kinase pathway. This pathway has four canonical branches, including extracellular 
signal-regulated kinase 1/2 (ERK1/2), p38, c-Jun N terminal kinase (JNK), and ERK5 (10). As 
Fam83d overexpression significantly inhibits myogenic differentiation, we hypothesized it may 
be acting though inhibition of the MAP kinase pathway. Indeed, Fam83d overexpression 
significantly reduced ERK1/2 phosphorylation, while ERK1/2 protein levels were also reduced, 
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albeit to a lesser extent. Interestingly, MEK1/2 protein levels were not affected by Fam83d 
overexpression, while phosphorylation status of MEK1/2 was only mildly inhibited by Fam83d 
ectopic expression. To confirm that Fam83d-mediated inhibition of ERK1/2 phosphorylation 
results in a change in the MAPK signaling cascade, we evaluated the activity of the downstream 
transcription factor AP-1. When C2C12 cells were transfected with increasing concentrations of 
Fam83d, we saw a corresponding decrease in the activity of an AP-1 reporter gene in a dose-
dependent fashion. Taken together, this data suggests that Fam83d inhibits MAPK signaling 
specifically though the ERK1/2 branch by imposing its effects downstream of MEK1/2. Previous 
studies have also observed an effect of Fam83d on MAPK signaling. In hepatocellular carcinoma 
cell culture, Fam83d overexpression was shown to increase phosphorylation levels of both 
MEK1/2 and ERK1/2 (25). Another study investigating the role of Fam83d in ovarian cancer 
saw a similar increase in ERK1/2 phosphorylation when Fam83d was overexpressed in cell 
culture (38). The findings of this study provide further evidence for the involvement of Fam83d 
in the ERK branch of MAPK signaling but suggest the mechanism of that involvement may be 
different between skeletal muscle and various cancer types. This is not wholly unexpected as 
cancer represents an aberration of normal cell signaling. The ERK1/2 branch of the MAP kinase 
pathway is active during myoblast proliferation, decreases as cells differentiate, and then peaks 
again at terminal differentiation and during myoblast fusion (11). As Fam83d expression is 
highest during proliferation, it is possible that Fam83d is influencing this first phase of ERK1/2 
activation. Since expression of both proteins decrease as cells enter differentiation, we evaluated 
the effect of MEK and ERK inhibition though the use of the small molecule inhibitors 
GSK1120212 or SCH772984, respectively. Data from this experiment revealed that inhibition of 
MEK or ERK was sufficient to significantly increased Fam83d levels during muscle cell 
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differentiation. This suggests there may be some coordination of protein turnover involving both 
Fam83d and the ERK1/2 branch of the MAPK signaling pathway as each appears to inhibit the 
other.  
 
Another important molecular component of muscle development and growth is the AKT 
signaling pathway. AKT is a kinase that is activated in response to insulin signaling and can 
modulate the activity of several downstream targets, including mTOR and GSK-3β (11). 
Phosphorylation of mTOR by AKT is an activating event that leads to an increase in protein 
synthesis. GSK-3β has been shown to inhibit differentiation and hypertrophy and 
phosphorylation by AKT relieves this inhibition (11). To further elucidate the function of 
Fam83d, we investigated its possible role in the AKT pathway. Overexpression of Fam83d 
greatly reduced both total AKT protein levels, as well as, the amount of phosphorylated AKT in 
C2C12 cells. Surprisingly, Fam83d overexpression did not significantly reduce mTOR 
phosphorylation at serine 2448, the primary site of AKT phosphorylation. Overexpression of 
Fam83d did not appear to effect GSK-3β protein levels, but did cause a small, but significant 
decrease in GSK-3β phosphorylation levels. 
 
These data suggest Fam83d may have a role in negatively regulating AKT activity as part of the 
atrophy cascade. Interestingly, other investigations have also found Fam83d to be involved in 
AKT signaling (22, 29). A study looking at the role of Fam83d in breast cancer showed that 
overexpression of Fam83d increased the amount of mTOR phosphorylation (22). Another study 
investigating ovarian cancer also observed an increase in AKT and mTOR phosphorylation in 
response to Fam83d overexpression (29). As with the results from the effect of Fam83d on 
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ERK1/2 signaling, these results suggest that Fam83d is working via a different mechanism in 
skeletal muscle than in cancers.  
 
Fam83d is one of an eight-member family of proteins that all have DUF1669 in common, which 
is a domain of unknown function located at the N-terminus of each protein. While the amino acid 
sequence of this highly conserved region provides few clues as to the function of the domain, it 
does contain an HxKxxxxD (HKD) motif that is characteristic of a phospholipase D-like (PLD-
like) domain (39). Typically, proteins that have phospholipase D catalytic activity contain two 
PLD domains, and these domains interact to form the catalytic core within the protein (39). 
Fam83d contains only one such HKD motif and, to date, there is no evidence that Fam83d 
possess canonical PLD activity. A recent study found that DUF1669 was both necessary and 
sufficient for the association between Fam83 family members and members of the casein kinase 
1 (CSNK1) family, which has resulted in a proposed renaming of DUF1669 to polypeptide 
anchor of casein kinase 1 (PACK1) (32). This same study demonstrated that different CSNK1 
isoforms have affinity for specific Fam83 family members, and Fam83d was shown to associate 
specifically with CSNK1α1 and CSNK1α1-like (32).  
 
To further elucidate the role of Fam83d in skeletal muscle, co-immunoprecipitation experiments 
using C2C12 cells revealed that Fam83d does indeed associate with CSNK1α1. To investigate the 
mechanism of this interaction, site-directed mutagenesis was used to create a double mutation 
within the HKD motif resulting in the creation of the Fam83d- H239N/K241Q mutant (Fig. 11A, 
green asterisks signify mutated amino acids). Disruption of the HKD motif significantly 
diminished the interaction between Fam83d and CSNK1α1 in muscle cells. Interestingly, 
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overexpression of Fam83d-H238N/K241Q resulted in a significant increase in CSNK1α1 levels 
in differentiated myotubes, while overexpression of Fam38d-WT led to significant 
destabilization of CSNK1α1 in proliferating myoblasts. A recent study examined FAM83D and 
CSNK1α1 binding in the human osteosarcoma cell line U2OS by mutating two different amino 
acids also contained within DUF1669; F283A and D249A. Each of these substitutions on their 
own were sufficient to ablate the Fam83d/CSNK1α1 interaction (33). These results together 
suggest that the binding of CSNK1α1 to Fam83d likely involves numerous amino acids in the 
DUF1669 region and that mutation of any of these residues greatly disrupts the interaction 
between Fam83d and CSNK1α1. In the current study, we also generated a Fam83d-F280A 
mutant (equivalent to the human FAM83D-F283A mutation) and found that the 
Fam83d/CSNK1α1 interaction was significantly diminished. Interestingly, the Fam83d-F280A 
mutant did not stabilize CSNK1α1 in differentiated myotubes as was observed with Fam83d-
H239N/K241Q double mutant overexpression. Furthermore, like wild-type Fam83d, the F280A 
mutant was still able to inhibit ERK1/2 phosphorylation, while the H239N/K241Q mutant was 
unable to inhibit ERK1/2 phosphorylation. These novel and intriguing observations suggest that 
the putative PLD-like domain may play a functional role in CSNK1α1 stability and ERK1/2 
phosphorylation in muscle cells.  
 
The discovery that Fam83d is induced in response to denervation furthers our understanding of 
the molecular genetic events of neurogenic atrophy. This study identifies Fam83d as having 
novel, muscle specific, expression and function. Fam83d is both transcriptionally active and 
highly expressed during myoblast proliferation and is rapidly downregulated and degraded as 
cells begin differentiation. Fam83d overexpression negatively regulates both the ERK1/2 branch 
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of MAP kinase signaling, as well as, AKT signaling. This regulation appears to involve the HKD 
motif located within DUF1669 at the N-terminal region of the protein and disruption of this 
motif reverses the negative effects. Fam83d also physically associates with and destabilizes 
CSNK1α1 in skeletal muscle and this association and destabilization is at least partially mediated 
by the HKD motif. Although further investigation is needed to elucidate the precise function of 
this gene, this study furthers our current understanding of the molecular and cellular events of 
muscle atrophy and suggests that Fam83d may play a functional role in muscle cell 
































Chapter 3: Identification and Functional Analysis of Dual Specificity Phosphatase and Pro 




Overview of Dupd1 
 
Dupd1 is categorized as an atypical dual specificity phosphatase (DUSP) capable of 
dephosphorylating both phosphotyrosine and phosphoserine/phosphothreonine residues within 
the same substrate (40).  Dupd1 is evolutionarily conserved, sharing 87% identity with human 
and 91% identity with rat (41). In mice, Dupd1 is highly expressed in skeletal muscle, liver and 
adipose tissue (41). Interestingly, the human mRNA of Dupd1 has only been detected in skeletal 
muscle (http://www.proteinatlas.org/ENSG00000188716-DUPD1/tissue). When the open 
reading frame associated with Dupd1 was initially identified, it was predicted to include a 
proline isomerase and a DUSP region but further investigation showed the transcript does not 
include the proline isomerase, making dual specificity phosphatase and pro isomerase domain 
containing 1 a bit of a misnomer (41). Dupd1 was renamed to Dusp27 in a 2007 paper, causing 
confusion with another atypical DUSP that is identified by the same name (41). For clarity, the 
subject gene of this study will continue to be referred to as Dupd1 until the nomenclature has 
been definitively determined. Dupd1 has been the focus of few previous studies and its role in 
skeletal muscle atrophy is completely unknown. As a phosphatase, the role of Dupd1 may lie in 
modulation of intracellular signaling. 
 
 





The C2C12 immortalized mouse myoblast cell line was obtained from the American Type Culture 
Collection (Manassas, VA) and maintained in DMEM (Life 163 Technologies, Grand Island, 
NY) supplemented with 10% fetal bovine serum (FBS) (GE164 Healthcare HyClone 
Laboratories, Logan, UT), non-essential amino acids, gentamicin, penicillin and streptomycin 
(all from Life Technologies, Grand Island, NY).  Cells were grown in a humidified chamber at 
37⁰C at 5% CO2. Cells were switched to DMEM supplemented with 2% serum, non-essential 
amino acids, gentamicin, penicillin and streptomycin 48 hours post-plating to stimulate myotube 
differentiation (Waddell, 2016).   
 
RNA Isolation and cDNA synthesis  
Total RNA was isolated from C2C12 myoblast cells using the RNeasy Mini Kit (Qiagen, 
Valencia, CA) according to the manufacturer's protocol. Purified RNA (1µg) was reverse-
transcribed using Oligo-dT primers and Moloney Murine Leukemia Virus (M-MLV) Reverse 
Transcriptase according to the manufacturer's protocol (Life Technologies, Grand Island, NY) 
 
Amplification and cloning of the full length Dupd1 cDNA 
For the amplification of Dupd1 cDNA, gene-specific primer pairs were designed (see Table 1) 
using the gene sequences from Mus musculus (GenBank accession number: NM_001013826). 
PCR was performed according to the manufacturer's protocol (Life Technologies, Grand Island, 
NY) using Taq DNA polymerase, and template prepared by reverse transcription of RNA 
isolated from C2C12 cells as described above utilizing gene specific primer pairs (Table 1). 
Amplicons were cloned into the pGEM-T Easy vector (Promega, Madison, WI) according the 
manufacturer's protocol and sequenced using the Big Dye Sanger terminator sequencing method 
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(Eurofins MWG Operon, Huntsville, AL) to confirm amplification of the expected target and the 
absence of mutations. The Dupd1 cDNA was sub-cloned into the Xho1 and Bam HI restriction 
sites of pcDNA3.1 (+) (Life Technologies, Grand Island, NY) and sequenced to confirm correct 
orientation. The Dupd1 cDNA was also sub-cloned into the Xho1 and Bam HI restriction sites of 
the pEGFP-C3 expression plasmid (Clontech, Mountain View, CA) and sequenced to confirm 
correct orientation and in frame fusion with GFP. The Dupd1 cDNA fused to myc and DDDDK 
tags and cloned into the pCMV6-Entry vector was purchased from OriGene Technologies 
(Rockville, MD)..  
 
Promoter cloning of the Dupd1 gene 
Genomic DNA was isolated from C2C12 cells using the DNeasy Blood and Tissue Kit (Qiagen, 
Valencia, CA) according to the manufacturer's protocol and used as template for the 
amplification of the proximal regulatory region of Dupd1. PCR was performed using Dupd1 
promoter region-specific primer pairs (see Table 1) developed using mouse genomic sequences 
obtained from the Ensembl database (www.ensembl.org). PCR reactions were performed using 
Taq DNA polymerase and genomic mouse DNA according to the manufacturer's protocol (Life 
Technologies, Grand Island, NY). The PCR amplicons were cloned into the pGEM-T Easy 
vector (Promega,Madison,WI) according to the manufacturer's protocol and sequenced to 
confirm amplification of the predicted target region and the absence of mutations. The Dupd1 
promoter fragments (~500, ~1000 and ~2000 base pairs) were sub-cloned into the Mlu I and 
Hind III sites of the pSEAP2-Basic reporter plasmid (Clontech, Mountain View, CA) to create 
the pSEAP-Dupd1-Pro500, the pSEAP-Dupd1-Pro1000 and the pSEAP-Dupd1-Pro2000 reporter 





C2C12 myoblast cells were plated into 12 well plates at a density of 75,000 cells/well in DMEM 
+ 10% FBS (proliferation media) and cultured overnight. All conditions were assessed in 
triplicate. Transfections were performed utilizing Turbofect Transfection Reagent (Thermo 
Scientific, Rockford, IL) following the manufacturer’s protocol. Media was refreshed 1 hour 
prior to transfection. 1 μg of total DNA (250 ng/well of reporter plasmid, 125 ng/well of β -
galactosidase (β-gal) as the internal control plasmid, and empty pBluescript vector as filler DNA 
to 1 μg DNA/well) was allowed to complex with transfection reagent for 20 minutes prior to 
overlaying the cells. Following 24-hour incubation with the transfection reaction, the 
proliferation media was replaced with differentiation media (DMEM + 2% serum) and incubated 
for an additional 1-7 days until reporter assays were performed.  
 
SEAP reporter gene assays 
Growth media was collected from C2C12 mouse myoblasts at 1-7 days after the switch to 
differentiation media post-transfection and tested for SEAP levels using the Phospha‐Light 
SEAP Reporter Gene Assay Kit and following the manufacturer’s instructions (Life 
Technologies, Grand Island, NY). The level of SEAP generated luminescence was assessed with 
a Synergy 2 microplate reader programmed for an endpoint read and a 2 s integration time. At 
the conclusion of the experiment, cells were lysed with Passive Lysis Buffer (Promega, Madison, 
WI), lysates were centrifuged to clear cell debris, and assessed for β‐galactosidase (β‐gal) 
activity. The SEAP activity numbers were corrected with β‐gal activity numbers to adjust for any 




Bioinformatic analysis of Dupd1 
DNA sequences corresponding to the promoter regions of human, rat, and mouse Dupd1 
(Ensembl Transcript ID: ENSG00000188716.5, ENSRNOG00000013034.5, and 
ENSMUSG00000063821.6, respectively) starting at ‐2000 and including the first exon were 
taken from the Ensembl database (www.ensembl.org) and analyzed using the Clustal Omega 
multiple sequence alignment tool available on the EMBL‐EBI website 
(https://www.ebi.ac.uk/Tools/msa/clustalo/). The Clustal Omega alignment data was then 
analyzed using Boxshade version 3.21 (http://www.ch.embnet.org/software/BOX_form.html) 
that is available on the ExPASy (www.expasy.org) website. The polypeptide sequences for 
human, mouse, and rat Dupd1 were also downloaded from Ensembl and aligned using the 




Total RNA was isolated from proliferating and differentiated C2C12 cells as described above. 
Purified total RNA (1.0 μg) was reverse‐transcribed using the iScript cDNA Synthesis Kit 
according to the manufacturer’s protocol (Bio‐ Rad, Hercules, CA). cDNA amplification was 
conducted using the iTaq Universal SYBR Green Reaction Supermix and gene specific primers 
(see Table 1) according to the manufacturer’s protocol (Bio‐Rad, Hercules, CA). Samples were 
analyzed using a CFX Connect Real‐Time PCR Detection System (Bio‐Rad, Hercules, CA) and 
gene expression levels of Dupd1 at PD2, DD2 and DD7 were quantitated. Each timepoint was 
performed in biological triplicates, each individual biological replicate was used for cDNA 
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synthesis in duplicate, and each cDNA synthesis replicate was analyzed in technical triplicates 
(three biological replicates × two cDNA synthesis replicates × three technical replicates = 18 
individual reads per biological sample) and the experiment was repeated at least twice. Relative 
gene expression was calculated using the 2−ΔΔCt Livak method and using GAPDH as the 
reference gene. 
 
Protein purification and Western blot analysis  
C2C12 cells were cultured in 10 cm culture dishes and Dupd1 was exogenously expressed by 
transfecting the cells with the pCMV6‐Dupd1-myc-DDK or pcDNA3.1-Dupd1 expression 
plasmid 24 h post‐plating. The Dupd1 overexpression time course was collected by harvesting 
cells 48 h post‐plating (PD2), as well as cells cultured for an additional 1, 3 or 5 days in 
differentiation media (DD1, DD3, DD5). The collected cells were spun down and kept at −80°C 
until cell homogenization and protein isolation was performed. 
 
The harvested cells were incubated on ice for 30 min, with agitation every 10 minutes, in 
Universal Lysis Buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 50 mM NaF, 0.5% NP‐40), plus 
additions (1 mM PMSF, 1 mM DTT, 10 mM β-glycerophosphate, 2 mM sodium molbydate, and 
a protease inhibitor cocktail). Cell homogenates were centrifuged to clear cellular debris and 
protein concentrations were determined using the Quick Start Bradford 1× Dye Reagent (Bio‐
Rad, Hercules, CA) following the manufacturer’s instructions. 
 
Western blots were conducted using 75-100 μg of protein on a 10% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis denaturing gel and then transferring overnight to 
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polyvinylidene fluoride membrane (EMD Millipore, Billerica, MA). Membranes were stained 
with Ponceau S to visualize equal protein loading and successful transfer and then incubated with 
blocking solution (5% w/v dry milk in tris‐buffered saline with 0.05% Tween‐20). Western blot 
membranes were incubated with antibodies listed in Table 2, followed by probing with an 
appropriate HRP‐conjugated secondary antibody (Santa Cruz Biotechnology, Dallas, TX) and 
visualized using ECL substrate (Pierce/Thermo Fisher Scientific, Rockford, IL). Polyvinylidene 
difluoride (PVDF) membranes were stripped by incubating for 20-30 min in stripping buffer 
(10% SDS, 0.5 M tris-HCl pH 6.8 and β-mercaptoethanol) at 50°C, and then blocked, probed, 
and visualized again as described above. Western blot band intensity quantifications were 
conducted using the open access ImageJ software. 
 
Confocal Fluorescence Microscopy 
C2C12 cells were plated on Cellvis (Sunnyvale, CA) 35 mm glass bottom dishes and transfected 
24 h after cells were plated with either the pEGFP‐C3 or pEGFP‐Dupd1 plasmids duplexed with 
TurboFect Reagent (Thermo Fisher Scientific, Rockford, IL) as per the manufacturer’s 
instructions. Before imaging, the cells were washed with phosphate buffered saline, fixed with 
paraformaldehyde dissolved in sodium cacodylate, and stained with DRAQ5 fluorescent DNA 
dye (Biostatus, Leicestershire, UK). The images were acquired using an Olympus Fluoview FV‐
1000 confocal fluorescent microscope equipped with Super Apochromat UPLSAPO 20X and 
Super Apochromat UPLSAPO 60XW objectives. Open access ImageJ software combined with 






C2C12 cells were grown in 10% FBS DMEM media and transfected with pCMV6-Dupd1-myc-
DDK expression plasmid and harvested 24 hours post-transfection. Cells were lysed on ice for 
30 minutes in ULB (+) (50 mM Tris, pH 7.5, 150 mM NaCl, 50 mM NaF, 0.5% NP-40, 1 mM 
PMSF, 1 mM DTT, 10 mM β-glycerophosphate, 2 mM sodium molbydate, and protease 
inhibitor cocktail). Homogenates were cleared by centrifugation and protein concentrations were 
quantified using the Quick Start Bradford 1X Dye Reagent (Bio-Rad, Hercules, CA) according 
to the manufacturer’s protocol. 500 μg protein was diluted in ULB and precleared with protein 
A/G agarose beads (Pierce/Thermo Scientific, Rockford, IL) for 1 h at 4°C with constant end-
over-end rotation. Beads were cleared from solution via centrifugation and the supernatant was 
incubated with 2 μg of anti-myc (60003-2-lg; ProteinTech, 318 Rosemont, IL) antibody for 4 h at 
4°C with constant end-over-end rotation. Protein A/G agarose beads were added to solution and 
incubation was continued for 6 additional hours. Beads were cleared from solution via 
centrifugation and pelleted beads were washed 3X with ULB, and then boiled for 5 mins at 
95°C. 50 μg of protein lysate was used for input control and SDS-PAGE was performed. 
Separated proteins were then transferred to a PVDF membrane and probed using the antibodies 
listed in Table 2. .  
 
Statistics 
Data are presented as the mean ± standard deviation (SD). Statistical analysis was conducted 
using a two-tailed t-test and a difference was considered statistically significant at a P value < 
0.05. 
 
Table 3. List of primers used in the Dupd1 study 
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Table 4. List of antibodies used in the Dupd1 study 
Antibody Source Catalog # Dilution 
anti-Dusp27 Santa Cruz Biotechnology, Dallas, TX Sc-515513 WB: 1:250 
anti-myc ProteinTech, Rosemont, IL 60003-2-lg  WB: 1:2000 
 IF: 1:50 
anti-α-tubulin Santa Cruz Biotechnology, Dallas, TX sc-32293  WB: 1:1000 
anti-Myosin Heavy 
Chain (MYH1/2/4/6) 
Santa Cruz Biotechnology, Dallas, TX sc-32732  WB: 1:1000 
anti-myogenin Santa Cruz Biotechnology, Dallas, TX sc-12732  WB: 1:1000 
anti-GAPDH ProteinTech, Rosemont, IL 60004-1-lg  WB: 1:5000 
anti-phospho-ERK Santa Cruz Biotechnology, Dallas, TX sc-7383 WB: 1:1000 
anti-ERK Santa Cruz Biotechnology, Dallas, TX sc-94  WB: 1:1000 
anti-Akt1-phospho-
S473 
ProteinTech, Rosemont, IL 66444-I-lg WB: 1:2000 
anti-Akt ProteinTech, Rosemont, IL 60203-2-lg  WB: 1:5000 
anti-phospho-mTOR-
Ser2448 
Cell Signaling Technology, Danvers, MA 5536  WB: 1:2000 
anti-phospho-mTOR-
Ser2481 
Cell Signaling Technology, Danvers, MA 2974 WB: 1:2000 
anti-mTOR ProteinTech, Rosemont, IL 66888-1-lg WB: 1:10000 
anti-phospho-4E-BP1 
(Thr37/46) 
Cell Signaling Technology, Danvers, MA 2855 WB: 1:1000 
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anti-4EBP1 ProteinTech, Rosemont, IL 60246-1-lg WB: 1:2000 
Anti-phospho-p70 S6 
Kinase (Thr389) 
Cell Signaling Technology, Danvers, MA 9205 WB: 1:1000 
Anti p70(S6K) ProteinTech, Rosemont, IL 66638-1-lg WB: 1:4000 
anti-phospho-AMPKα 
(Thr172) 
Cell Signaling Technology, Danvers, MA 2535 WB: 1:1000 




Cell Signaling Technology, Danvers, MA 4161  WB: 1:1000 
Anti-Glucocorticoid 
receptor 
ProteinTech, Rosemont, IL 66904-1-lg WB: 1:5000 
Anti-GFP tag ProteinTech, Rosemont, IL 66002-1-lg WB: 1:5000 
anti-DDK ProteinTech, Rosemont, IL 20543-1-AP  WB: 1:5000 
Mouse anti-rabbit IgG-
HRP 
Santa Cruz Biotechnology, Dallas, TX sc-2357 WB: 1:5000 
Rabbit anti-mouse IgG-
HRP (H+L) 




Dupd1 is upregulated during neurogenic skeletal muscle atrophy  
 
RNA was isolated from control and denervated mouse gastrocnemius and soleus muscles as 
previously described (5) and an Illumina mouse‐6 v1.1 microarray was performed at 3 days and 
14 days post-denervation. Analysis of the microarray data submitted to the NCBI Gene 
Expression Omnibus (GEO) revealed a significant number of genes that show differential 
expression patterns in response to neurogenic muscle atrophy. Many of these genes have not 
previously been characterized in skeletal muscle nor implicated in atrophy. Dupd1 showed low 
basal levels of expression in control gastrocnemius and soleus muscles. However, in the 
denervated tissue, Dupd1 was shown to be significantly upregulated at day 3 and day 14 post-




Dupd1 is composed of three coding and one non-coding exons, is located on chromosome 14 in 
mice, and shows strong architectural conservation between mouse, rat, and human (Fig. 20B).    
 
 
Figure 20. Dupd1 is upregulated during skeletal muscle atrophy. A) Whole genome expression 
analysis was conducted on triceps surae muscle from wild-type (WT) mice after 3 days (3D) and 
14 days (14D) of denervation. Each condition represents the average expression from three 
animals and error bars represent ±SD. White bars, controls (Con); black bars, denervated (Den). 
Significant difference between denervated mice and control mice in the same group (**:P < .01). 
B) Schematic of the Dupd1 transcript in mouse. Darkened rectangles represent the exons 
containing the translated region, open rectangles represent exons containing the untranslated 
regions, and the lines connecting these rectangles represent introns 
 
 
Dupd1 is expressed during late muscle cell differentiation 
 
To measure the transcriptional activity of Dupd1, total RNA was harvested from C2C12 mouse 
myoblasts during proliferation (PD2), as well as an early (DD2) and late (DD7) differentiation 
timepoints. cDNA synthesized from this RNA was used to conduct RT-qPCR using Dupd1 
specific primers listed in Table 3. Two sets of primer pairs were utilized to compare expression 
between an amplicon containing part of the non-coding first exon and an amplicon lacking any 
of the non-coding first exon. The qPCR analysis showed Dupd1 mRNA levels to be substantially 
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higher during late differentiation compared to either proliferation or early differentiation 
timepoints for both primer pairs (Fig. 21).  
 
Figure 21. Dupd1 is significantly upregulated during muscle cell differentiation. Dupd1 mRNA 
increases significantly during late differentiation compared to either proliferation or early 
differentiation. Quantitative polymerase chain reaction (qPCR) utilizing cDNA generated from 
RNA isolated from C2C12 cells harvested at proliferation day 2 (PD2), differentiation day 2 
(DD2) and differentiation day 7 (DD7). Cells were maintained in proliferation media (10% 
serum) and harvested at 2 days post-plating and the remaining cells were switched to 
differentiation media (2% serum) and harvested at 2- and 7-days post-media change. Significant 
difference between Dupd1 expression in differentiated cells compared to Dupd1 expression in 
proliferating cells (*:P < .05, **:P < .01, ****:P< .0001). 
 
 
Dupd1 is regulated by Myogenic Regulatory Factors 
To evaluate how the proximal promoter region of Dupd1 is regulated within muscle cells, 
approximately 500 and 1000 base pairs of the promoter were cloned using the primers listed in 
Table 2. The fragments were then fused to a secreted alkaline phosphatase (SEAP) reporter 
plasmid to create the pSEAP-Dupd1-Pro500 andpSEAP-Dupd1-Pro1000 reporter constructs. The 
constructs were then transfected into C2C12 mouse myoblasts and SEAP assays were preformed 
48 hours after the change to differentiation media. Promoter activity was assessed by secreted 
alkaline phosphatase activity. Both the 500 and 1000 base pair fragments show low endogenous 
expression at DD2 (Fig. 22A). However, endogenous activity of the 500 and 1000 base pair 
fragments were significantly upregulated at DD7 compared to the proliferation and early 
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differentiation timepoints, mirroring the endogenous mRNA expression as determined by qPCR 
(Fig. 22B). Interestingly, co-transfection with a MyoD or myogenin expression plasmid resulted 
in dramatic induction of both the 500 and 1000 bp promoter fragments (Fig. 22A). Myogenic 
regulatory factors, such as MyoD and myogenin, regulate gene transcription through interaction 
with E-box consensus elements found in the promotors of muscle-specific genes. Bioinformatic 
analysis of the first 500 base pairs of the promoter of Dupd1 revealed five such elements, two of 
which are conserved between humans and rodents (Fig. 22C). Site-directed mutagenesis was 
used to disrupt each of the two conserved E-box elements individually and in combination. 
Disruption of either E-box resulted in a dramatic blunting of the induction of the Dupd1-Pro500 
seen with MyoD overexpression, while disruption of both E-boxes simultaneously eliminated the 







Figure 22. Cloning and analysis of the proximal regulatory region of the Dupd1 gene locus. (A) 
C2C12 myoblasts were transfected with reporter plasmids containing 500 bp or 1000 bp of the 
Dupd1 promoter fused to the Secreted Alkaline Phosphatase (SEAP) reporter gene alone or in 
combination with either a MyoD or myogenin expression plasmid. Each condition was 
performed in triplicate and each experiment was repeated at least three times (n = 3). The graphs 
are of a representative experiment and values correspond to the mean relative light unit (RLU) 
values ±SD. Significant difference between the empty control reporter plasmid (pSEAP2-Basic) 
and the pSEAP2-Dupd1 reporter constructs, (*: P < .0001). Significant differences between the 
activities of the pSEAP2-Dupd1-Pro reporter constructs with and without MyoD or myogenin 
ectopic expression (B) C2C12 myoblasts were transfected with a reporter plasmid containing the 
SEAP reporter gene fused to either 500 bp or 1000 bp of the Dupd1 proximal promoter or an 
empty reporter plasmid. Each condition was performed in triplicate and assays were performed at 
PD2 and DD7. Numbers correspond to the mean relative light unit (RLU) values ±SD. 
Significant difference between the reporter constructs activity at PD2 and reporter constructs 
activity at DD7 (*: P < .0001). (C) Schematic and sequence alignment of the Dupd1 regulatory 
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region. Promoter sequences from mouse, rat, and human Dupd1 (2000 base pairs upstream of the 
transcription start site (+1) through the first exon) were downloaded from the Ensembl database 
(www.ensembl.org) and aligned using the ClustalW algorithm. Approximate positions of 
putative transcription factor binding sites are indicated in the schematic of the Dupd1 regulatory 
region at the top. Putative consensus E-box elements 5′-CANNTG-3′ (Red diamond, conserved 
and yellow triangle, non-conserved) and TATA box (green square) are indicated. N represents 
any nucleotide. Conserved nucleotides are highlighted in black, transitions are highlighted in 
gray, and transversions are highlighted in white. (D) C2C12 myoblasts were transfected with the 
pSEAP-Dupd1-Pro500 wild-type,pSEAP-Dupd1-Pro500-Ebox-1-Mutant, pSEAP-Dupd1-
Pro500-Ebox-2-Mutant, or pSEAP-Dupd1-Pro500-Ebox-1/2-Mutant reporter plasmids. The 
media was then assayed for SEAP activity at 72 hours following the switch to differentiation 
media. All conditions were performed in triplicate and each experiment was repeated at least 
once. The graphs are of a representative experiment and numbers correspond to the mean relative 
light unit (RLU) values ± SD. Significant differences between the activities of the pSEAP-
Dupd1-Pro500 wild-type reporter constructs and the pSEAP-Dupd1-Pro500-Ebox mutant 
reporter constructs, (*: P < 0.001). 
 
 
Subcellular localization of Dupd1 
 
Dupd1 is located on chromosome 14 in mice and encodes a protein of 220 amino acids with a 
predicted molecular weight of 27 kDa. It contains a phosphatase domain with an active catalytic 
motif (Fig. 23A). To further characterize Dupd1 in skeletal muscle, the cDNA was cloned and 
fused to a GFP plasmid to allow for analysis of subcellular localization by confocal fluorescent 
microscopy. C2C12 cells were transfected with either an empty GFP expression plasmid or the 
Dupd1-cDNA-GFP expression plasmid and analyzed 24 hours post-transfection. The control 
GFP expression plasmid shows uniform GFP localization throughout the cell (Fig. 23B, Panels 
1-3). Cells transfected with Dupd1 fused to GFP also showed ubiquitous distribution throughout 
the cell, (Fig. 23B, Panels 4-12). The Dupd1-GFP expression plasmid was sequenced to confirm 
Dupd1 inframe fusion with GFP and correct orientation. C2C12 myoblasts were transfected with 
either an empty GFP expression plasmid or the Dupd1-GFP construct and protein lysates were 
used for Western blots.. Probing with an anti-GFP antibody demonstrated the correct shift in size 
in the Dupd1 containing plasmid compared to GFP alone. These findings together confirm that 
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the Dupd1-GFP expression plasmid is truly expressing GFP-tagged Dupd1 that localizes 






Figure 23. Dupd1 localizes to the cytoplasm and nucleus of myoblast cells. (A) Sequences of the 
mouse, rat, and human Dupd1 protein were downloaded from the Ensembl database and aligned 
using the ClustalW2 algorithm. Approximate position of the phosphatase domain is highlighted 
in green with the active motif within that domain highlighted in blue. (B) Proliferating C2C12 
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cells (PD2) transfected with the empty pEGFP-C3 expression vector were imaged at 10× (Panels 
1–3) and uniform cellular localization of GFP was observed. Representative C2C12 cells 
transfected with a pEGFP-Dupd1 expression plasmid were imaged at proliferation day 2 (PD2) 
at 10× (Panels 4–6), 60× (Panels 7–9), and 100× (Panels 10–12) and uniform cellular 
fluorescence was observed. Draq5, a cell permeable fluorescent DNA dye, was used to visualize 
cell nuclei. (C) NIH3T3 cells were transfected with either an empty pEGFP expression plasmid 
or pEGFP-Dupd1 expression plasmid. Cells were maintained in culture media and harvested 24 
hours post-transfection. Protein samples (25 µg, 50 µg, and 100 µg) from each condition were 
used for Western blot analysis and membranes were probed with an anti-GFP antibody.   
 
Ectopic expression of Dupd1 impairs muscle cell differentiation 
To investigate whether Dupd1 has an impact on muscle cell differentiation, C2C12 cells were 
transfected with a myc-tagged Dupd1 expression plasmid. Cells were then harvested, over a time 
course spanning proliferation (PD2) and several differentiation timepoints (DD1, DD3 and 
DD5). Protein was isolated from cells and evaluated for expression of myosin heavy chain 
(MyHC) and myogenin, canonical makers of muscle cell differentiation. Western blot analysis 
showed significantly lower levels of both myogenin and MyHC at all time points analyzed, with 
the greatest inhibition at DD3 (Fig. 24A). To quantify the amount of inhibition, Dupd1 was 
overexpressed in biological quadruplicate and harvested at day 3 of differentiation. Lysates were 
evaluated by Western blot and it was found that myogenin and MyHC expression were 
significantly reduced in samples ectopically expressing Dupd1 (Fig. 24B and C). Analysis with 
an anti-Flag antibody confirmed significant overexpression of Flag tagged Dupd1 in all 
transfected samples. GAPDH was used to confirm equal protein loading and it expression 






Figure 24. Ectopic expression of Dupd1 impairs muscle cell differentiation. C2C12 cells were 
transfected with a Dupd1-myc-Flag expression plasmid or mock transfected followed by 
Western blot analysis. (A) Western blot analysis of Flag, Myosin Heavy Chain (MyHC), and 
myogenin using protein homogenates from proliferating (PD) and differentiated (DD) C2C12 
cells harvested over a 5-day differentiation time course. Cells were maintained in proliferation 
media (10% serum) and harvested 2 days post-plating and the remaining cells were then 
switched to differentiation media (2% serum) and harvested at 1, 3 and 5-days post-media 
change. GAPDH was analyzed to confirm equal protein loading. The experiments were repeated 
at least three times and the Western blots shown are representative examples of the results 
obtained. (B) C2C12 cells were transfected with a Dupd1-myc-Flag expression plasmid or mock 
transfected in biological quadruplicates and cell lysates were then analyzed by Western blot for 
Flag, MyHC, and myogenin. Cells were maintained in proliferation media then switched to 
differentiation media (2% serum) for 3 days. GAPDH was analyzed to confirm equal protein 
loading. The experiment was performed in quadruplicate (n = 4). (C) Quantification of the 
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Western blot band intensities for Flag, MyHC, and myogenin in Part B. Relative intensity of 
each band was corrected to either GAPDH (shown) or α-tubulin band intensities for each 
corresponding biological replicate. Significant differences between control cells compared to 




Ectopic expression of Dupd1 attenuates MAP Kinase and AMPK protein expression 
 
As Dupd1 was previously shown to effect MAP kinase signaling though modulation of the 
ERK1/2 cascade in ovarian tissue, its potential role in this pathway in skeletal muscle was 
investigated (45). C2C12 cells were transfected with a reporter plasmid created by fusing the AP-
1 consensus element to a pSEAP-promoter plasmid in combination with increasing 
concentrations of the pcDNA3.1-Dupd1 expression plasmid. SCH772984, a validated ERK1/2 
inhibitor, was used as a positive control. Dupd1 overexpression repressed AP1 reporter activity 
in a dose dependent fashion, with the highest concentration of Dupd1 expression plasmid 
exhibiting a similar level of repression as SCH772984 (Fig. 25A). To further evaluate this effect, 
Dupd1 was overexpressed in C2C12 mouse myoblasts and harvested over a differentiation time 
course, as well as in biological quadruplicate as described above, and protein homogenates from 
these cells were evaluated by Western blot. Protein levels of ERK1/2 were not significantly 
different in Dupd1 overexpression samples. However, overexpression of Dupd1 reduced levels 
of ERK phosphorylation at all timepoints (Fig. 25B and C). Interestingly, Dupd1 seemed to 







Figure 25. Ectopic expression of Dupd1 attenuates MAP Kinase signaling. (A) C2C12 cells were 
transfected with an AP-1 reporter plasmid alone or in combination with 0.125 µg, 0.25 µg or 
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0.50 µg of the Dupd1-myc-Flag expression plasmid or treated with 2 µM of SCH772984, a 
validated ERK inhibitor. The media was then assayed for SEAP activity 48 h (DD2) following 
the switch to differentiation media and SEAP numbers were normalized to β-galactosidase 
activity to correct for variations in transfection efficiency. Each condition was performed in 
triplicate and each experiment was repeated at least three times (n = 3). The graphs are of a 
representative experiment and numbers correspond to the mean relative light unit (RLU) values 
±SD. Significant differences between the activities of the pSEAP2-AP-1-Pro reporter construct 
alone and in combination with either 2 µM SCH772984 or 0.5 µg Dupd1-myc-Flag expression 
plasmid , (**: P < .01). (B) C2C12 cells were transfected with a Dupd1-myc-Flag expression 
plasmid or mock transfected followed by Western blot analysis. Cells were maintained in 
proliferation media (10% serum) and harvested 2 days post-plating and the remaining cells were 
then switched to differentiation media (2% serum) and harvested 1, 3, and 5 days post-media 
change. Western blot analysis of phosphorylated-ERK1/2 (p-ERK1/2), pan-ERK1/2 (ERK1/2) 
using protein homogenates from proliferating (PD2) and differentiated C2C12 cells. The 
experiments were repeated at least three times (n = 3) and the Western blots shown are 
representative examples of the results obtained. (C) C2C12 cells were transfected with a Dupd1-
myc-Flag WT expression plasmid or mock transfected in biological quadruplicates. Western blot 
analysis of phosphorylated ERK1/2 (p-ERK1/2) and pan-ERK1/2 (ERK1/2) using protein 
homogenates from C2C12 cells differentiated for 3 days. The experiment was performed in 
quadruplicate (n = 4), repeated at least three times, and the blots shown are representative 
examples of the results obtained. (D) Quantification of the Western blot band intensities were 
measured for pan-ERK1/2 and the phospho-ERK1/2 to pan-ERK1/2 ratio Significant differences 
between control cells compared to cells ectopically expressing Dupd1, (**: P < .01, N.S. = not 
significant).  
 
A previous study found Dupd1interacts with AMPK (42). To evaluate if this relationship exists 
in muscle cells, the effect of Dupd1 overexpression on AMPK protein levels was evaluated by 
Western blot over a differentiation time course and AMPK protein levels were found to be 
significantly lower in the Dupd1 overexpression samples at all time points (Fig. 26A). To 
quantify this difference, control cells and cells overexpressing Dupd1 were harvested at DD3 in 
biological quadruplicate, and AMKP protein levels were quantified, revealing a significant 
decrease in total AMPK protein. Interestingly, the amount of AMPK phosphorylation is 
relatively constant between control cells and Dupd1 overexpressing cells and, considering the 
decrease in total AMPK, a significant increase in the ratio of AMKP phosphorylation in response 







Figure 26. Ectopic expression of Dupd1 attenuates AMPK signaling. C2C12 cells were 
transfected with a Dupd1-myc-Flag expression plasmid or mock transfected followed by 
Western blot analysis. Cells were maintained in proliferation media (10% serum) and harvested 2 
days post-plating and the remaining cells were then switched to differentiation media (2% 
serum) and harvested 1, 3, and 5 days post-media change. Western blot analysis of 
phosphorylated-AMPK (p-AMPK) and pan-AMPK (AMPK) using protein homogenates from 
proliferating (PD2) and differentiated C2C12 cells. The experiments were repeated at least three 
times (n = 3) and the Western blots shown are representative examples of the results obtained. 
(C) C2C12 cells were transfected with a Dupd1-myc-Flag WT expression plasmid or mock 
transfected in biological quadruplicates. Western blot analysis of phosphorylated-AMPK (p-
AMPK) andpan-AMPK (AMPK) using protein homogenates from cells differentiated for 3 days. 
The experiment was performed in quadruplicate (n = 4), repeated at least three times, and the 
blots shown are representative examples of the results obtained. (D) Quantification of the 
Western blot band intensities were measured for pan-AMPK and the phospho-AMPK to pan-
AMPK ratio. Significant differences between control cells compared to cells ectopically 
expressing Dupd1, (****: P < .0001). 
 
 




As dexamethasone treatment was previously shown to affect Dupd1 expression in mouse skeletal 
muscle, the role of Dupd1 on glucocorticoid signaling was evaluated (5). C2C12 mouse myoblasts 
were transfected with a reporter plasmid created by fusing four GRE consensus elements to a 
pSEAP-promoter plasmid in combination with increasing concentrations of the pcDNA3.1-
Dupd1 expression plasmid. Additionally, cells were treated with dexamethasone at DD6 for 12 
hours prior to the assay to induce the GR signaling pathway. Activity of the pSEAP-4X-GRE 
reporter plasmid increased with dexamethasone treatment, while Dupd1 overexpression 
significantly reduced this induction in a dose dependent manner (Fig. 27A). The proximal 
promoter region of MuRF1 contains a glucocorticoid response element (GRE), which has 
previously been shown to enhance transcription of MuRF1 in skeletal muscle (17). To evaluate if 
Dupd1 may be capable of regulating MuRF1, 500 base pairs of the proximal promoter region of 
MuRF1 was fused to the pSEAP2-Basic reporter plasmid and transfected into C2C12 mouse 
myoblasts in combination with pcDNA3.1-Dupd1 expression plasmid followed by 12 h of 
dexamethasone treatment. Consistent with previous findings, dexamethasone significantly 
increased the activity of the pSEAP-MuRF1-Pro500 reporter. Overexpression of Dupd1 






Figure 27. Dupd1 attenuates GR signaling. (A) C2C12 cells were transfected with a pSEAP-4X-
GRE reporter plasmid alone or in combination with 0.125 µg, 0.25 µg or 0.50 µg of the Dupd1-
myc-Flag expression plasmid and 5 µM dexamethasone (Dex). The media was then assayed for 
SEAP activity 48 h (DD2) following the switch to differentiation media and SEAP numbers were 
normalized to β-galactosidase activity to correct for variations in transfection efficiency. Each 
condition was performed in triplicate and each experiment was repeated at least three times (n = 
3). The graphs are of a representative experiment and numbers correspond to the mean relative 
light unit (RLU) values ±SD. (B) C2C12 cells were transfected with a MuRF1-Pro500 SEAP 
reporter plasmid alone, with 5 µM Dex or in combination the Dupd1-myc-Flag expression 
plasmid and Dex. SEAP activity was measured at DD2.  
 
As noted previously, Dupd1 expression was repressed in rat muscle tissue following 72 hours of 
dexamethasone treatment as evidenced by microarray (5). To assess if glucocorticoids can 
transcriptionally regulate Dupd1 in muscle cells, C2C12 mouse myoblasts were grown in culture, 
switched to differentiation media and then allowed to differentiate for six days. Starting at day 
six, cells were treated with dexamethasone for 72 hours and then harvested. Total RNA isolates 
were used to generate cDNA and qPCR was conducted to compare Dupd1 transcript levels 
between control and dexamethasone treated cells (Fig. 28). Results demonstrate a significant 




Figure 28. Dexamethsone treatment enhances Dupd1 mRNA expression. Quantitative 
polymerase chain reaction (qPCR) utilizing cDNA generated from RNA isolated from C2C12 
cells harvested at differentiation day 7 (DD7) with or without 72 h Dex. Cells were maintained in 
proliferation media (10% serum) and 2 days post-plating were switched to differentiation media 
(2% serum). Significant difference between endogenous Dupd1 expression compared to Dupd1 
expression in dexamethasone treated cells (****:P< .0001). 
 
 
To further investigate the relationship between Dupd1 and GR, Dupd1 was overexpressed in 
C2C12 mouse myoblasts and harvested over a differentiation time course and protein 
homogenates from these cells were evaluated by Western blot. Interestingly, Dupd1 
overexpression increased GR protein levels and phosphorylation status at all differentiation time 
points (Fig. 29A). To quantify this difference, control cells and cells overexpressing Dupd1 were 
harvested at DD5 in biological quadruplicate. Quantification revealed that Dupd1 overexpression 
significantly increases total GR protein levels, as well as GR phosphorylation. Comparison 
between GR protein levels and phosphorylation status indicated that not only is there an increase 
in GR protein levels, but there is also a significant rise in GR phosphorylation in response to 
Dupd1 overexpression (Fig. 29B and C).  Since GR exists within a chaperone complex while in 
the cytoplasm, the level of one of the major components of this complex, heat shock protein 90 
(HSP90), was also evaluated in biological quadruplicate at DD5 (Fig. 29B and C). Dupd1 






Figure 29. Dupd1 overexpression increases GR protein and phosphorylation levels. (A) C2C12 
cells were transfected with a Dupd1-myc-Flag expression plasmid or mock transfected followed 
by Western blot analysis. Cells were maintained in proliferation media (10% serum) and 
harvested 2 days post-plating and the remaining cells were then switched to differentiation media 
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(2% serum) and harvested 1, 3, and 5 days post-media change. Western blot analysis of 
phosphorylated-GR (p-GR) and pan-GR (GR) using protein homogenates from proliferating 
(PD2) and differentiated C2C12 cells. The experiments were repeated at least three times (n = 3) 
and the Western blots shown are representative examples of the results obtained. (B) C2C12 cells 
were transfected with a Dupd1-myc-Flag WT expression plasmid or mock transfected in 
biological quadruplicates. Western blot analysis of Flag (Dupd1-Flag), phosphorylated-GR (p-
GR), pan-GR (GR), and heat shock protein 90 (HSP90) using protein homogenates from C2C12 
cells differentiated for 3 days. The experiment was performed in quadruplicate (n = 4), repeated 
at least three times, and the blots shown are representative examples of the results obtained. 
GAPDH was used to confirm equal protein loading. (C) Quantification of the Western blot band 
intensities were measured for pan-GR, the phospho-GR to pan-GR ratio, HSP90, and Flag 
(Dupd1). Significant differences between control cells compared to cells ectopically expressing 






Skeletal muscle is a uniquely dynamic tissue and has remarkable ability to regulate its size and 
mass (9, 35). Skeletal muscle mass is maintained through a balance of protein synthesis and 
protein degradation and when this balance is shifted toward protein degradation, atrophy occurs 
(35). A wide range of events are capable of inducing this imbalance including denervation, 
starvation, disease, disuse, and aging (9). Much of the research in recent years has focused on 
degradation pathways, such as the ubiquitin proteasome system (UPS), however, the molecular 
mechanisms that underly these disparate atrophy-inducing events remain unclear. Dupd1 has 
been identified as a novel molecular component of the atrophy cascade as it is transcriptionally 
active in muscle and has been observed to be upregulated in response to neurogenic atrophy (5). 
There have been few previous studies that have focused on Dupd1 and this is the first to evaluate 
its role in the context of skeletal muscle atrophy.  
 
To characterize the regulation and expression of Dupd1 in muscle, qPCR was conducted using 
cDNA from C2C12 mouse myoblasts over a differentiation time course. These results showed that 
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Dupd1 is highly upregulated during late differentiation as compared to either proliferation or 
early differentiation. Additionally, the proximal promotor region was found to have endogenous 
expression that mirrors the transcription profile identified by qPCR. The promoter has low 
endogenous activity during cell proliferation but is highly upregulated during late differentiation. 
Additionally, even when endogenous activity is low the promotor has been shown to be highly 
inducible by myogenic regulatory factors (MRFs), specifically MyoD, and to a lesser extent, 
myogenin. MRFs can modulate activity of muscle-specific genes by binding of Ebox elements, 
of which there are two conserved Eboxes located in the proximal promoter region of Dupd1 (43). 
Disruption of either of these conserved Ebox sequences significantly diminishes the MyoD 
dependent induction and disruption of both all but ablates MRF-mediated induction. MyoD and 
myogenin are both is upregulated during muscle cell differentiation and act as a markers of 
myogenic commitment to the skeletal muscle lineage (43). Notably, MyoD and myognin are also 
significantly upregulated during neurogenic skeletal muscle atrophy, which may play a role in 
the upregulation of Dupd1 during both these processes (44). These findings together suggest that 
Dupd1 has a muscle-specific role and is highly sensitive to changes in the muscle cell 
environment. 
 
 Dupd1 is shown here to have a dramatic negative impact on muscle cell differentiation as 
evidenced by a stark decrease in both myosin heavy chain (MyHC) and myogenin protein levels, 
both canonical markers of differentiation in skeletal muscle. To further explore this effect, we 
evaluated the potential role of Dupd1 in several signaling pathways important for muscle cell 
growth and development. Dupd1 was previously shown to effect MAPK signaling though 
interaction with both the ERK1/2 and p38 branches of the pathway in ovary tissue (45). In the 
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current study, we find Dupd1 overexpression to inhibit MAPK signaling as evidenced by 
decreases in AP-1 reporter activity in C2C12 mouse myoblasts. Furthermore, Western blot 
analysis demonstrated that ERK1/2 phosphorylation was also inhibited by Dupd1 
overexpression. Interestingly, it appears there is a preference for dephosphorylation of ERK2 
(p42) over ERK1 (p44), as shown by an increased effect on the level of phosphorylation 
observed for the 42 kDa band compared to the signal to 44 kDa (Fig. 25B and C). Direct 
interaction between ERK1/2 and Dupd1 and p38 and Dupd1 was demonstrated by co-
immunoprecipitation using the ovarian cell line GG-CL (45). This interaction was not found in 
C2C12 mouse myoblasts nor did Dupd1 overexpression have any significant effect on p38 protein 
levels or its phosphorylation status (data not shown). Additionally, the effect of Dupd1 
overexpression on ERK1/2 phosphorylation appears more moderate than effects in the ovary 
(45). Taken together this suggests that the effect exerted by Dupd1 on MAPK signaling in 
skeletal muscle may be less robust in skeletal muscle than in the ovary. Rather than a direct 
physical interaction and potential dephosphorylation event, the effect observed in skeletal muscle 
may be a result of a downstream affect or an effect on another signaling pathway that 
tangentially regulates ERK1/2 signaling.  
 
AMP-activated protein kinase (AMPK) is a master regulator of energy homeostasis in virtually 
all eukaryotic cell types and is highly conserved across animals, plants, and yeast (46). As 
skeletal muscle plays a large role in metabolic homeostasis it is not surprising that AMPK is 
highly expressed in this tissue (46). AMPK is regulated by a wide variety of upstream signals 
and, through phosphorylation of a variety of transcription factors and co-factors, influences many 
pathways involved with both protein synthesis and protein degradation (46). Many residues on 
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AMPK are capable of being phosphorylated and one of the key residues for active kinase activity 
is Threonine 172 (47). AMPK becomes activated, primarily though phosphorylation of T172, in 
response to cellular stress and in turn activates pathways aimed at conserving existing ATP 
reserves, as well as increasing the supply of ATP (47). The current study demonstrates that 
Dudp1 overexpression significantly reduces AMPK protein levels while simultaneously 
increasing the proportionate amount of phosphorylation of T172. This increase in relative 
phosphorylation may be a compensatory mechanism in response to decreased protein levels or 
the result of a Dupd1-mediated dephosphorylation event that destabilizes hypophosphorylated 
AMPK in muscle cells. Interestingly, AMPK has also been previously shown to down regulate 
glucocorticoid receptor (GR) signaling, specifically through increasing phosphorylation at serine 
211 on GR (48).  
 
Glucocorticoids (GC) are key metabolic regulators in skeletal muscle (19). Increases in GCs 
decrease protein synthesis and increase protein degradation leading to skeletal muscle atrophy 
(19).  A previous study identified Dupd1 and being downregulated 7.2-fold in mouse triceps 
surae (TS) complexes during skeletal muscle atrophy induced by three days of systemic 
treatment with dexamethasone, a synthetic glucocorticoid. (5). The current study demonstrated 
that a Dupd1 reporter gene is transcriptionally upregulated by dexamethasone treatment, which is 
mirrored by RT-qPCR data showing that Dupd1 is upregulated in differentiated C2C12 cells in 
response to dexamethasone treatment. The discrepancy between the previous microarray study 
and the findings shown here highlight the complexity of atrophy signaling and the possibility of 
signaling pathway crosstalk that might be absent in a cell culture model. Despite these 
differences, evaluation in cell culture still provides valuable insights into muscle-specific 
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responses. Dupd1 overexpression has a dramatic effect on the glucocorticoid receptor. Total GR 
protein levels are significantly increased and phosphorylation of S211 is also increased. In many 
tissues, phosphorylation of S211 leads to a conformational change resulting in increased binding 
to glucocorticoid response elements (GRE) (49). However, in neuronal cells, liver cells, skeletal 
muscle, and adipose tissue, phosphorylation of the S211site has been shown to decrease 
signaling (48). This latter outcome is what was observed in C2C12 cells in response to 
overexpression of Dupd1, which resulted in an attenuation of the transcriptional activity of both 
the apSEAP-4X-GRE reporter construct and a MuRF1-Pro500 reporter construct containing a 
fragment of the MuRF1 promoter that includes a canonical GRE.   
 
Inactive glucocorticoid receptors reside in the cytoplasm bound in heat shock protein 90 
(HSP90) chaperone complexes (50). GR is activated by binding with glucocorticoids which 
results in disassociation from the chaperone complex and translocation to the nucleus (50). Once 
in the nucleus several GR-mediated responses are possible. GR may homodimerize and bind to 
GRE consensus elements, enhancing transcription of the genes they are associated with (20). 
Ligand-bound GR may also bind other transcription factors such as AP-1 or NF-κB to modulate 
their transcriptional activity (20). Additionally, monomeric GR may bind negative GREs 
(nGRE), resulting in transcriptional inhibition (20). Phosphorylation of GR either pre- or post-
ligand binding plays a role in determining which of these pathways GR will participate in (20). 
As a phosphatase, Dupd1 likely plays a role in the dynamic phosphorylation landscape regulating 
GR activity, resulting in the significant results described by this study. As a transcription factor, 
GR can have wide-ranging effects on the cellular signaling environment (51). GR can affect 
MAPK signaling though interaction with AP-1, as previously mentioned, and has also been 
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shown to inhibit ERK phosphorylation (51). It is possible that the reduction in ERK 
phosphorylation described in the current study is a result of downstream GR effects rather than 
direct dephosphorylation by Dupd1.   
 
The finding that Dupd1 expression is affected by multiple atrophy inducing stimuli furthers our 
understanding of the complex molecular signaling network that underlies this debilitating 
condition. This study demonstrates that Dupd1 overexpression dramatically inhibits muscle cell 
differentiation, possibly as a result of its effect on the multiple signaling pathways examined 
here. When Dupd1 was first characterized, it was predicted to be involved in the regulation of 
energy metabolism, based on its tissue expression profile (41). The current study supports that 
initial prediction by implicating Dupd1 as modulating two major pathways important for 
metabolic homeostasis; glucocorticoid receptor and AMP-activated protein kinase signaling. 
Although the precise molecular mechanisms responsible for the function of Dupd1 remains 
unclear, this study reveals Dupd1 as potentially having a role in muscle cell differentiation, 
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